US20090149460A1 - New Compounds - Google Patents

New Compounds Download PDF

Info

Publication number
US20090149460A1
US20090149460A1 US12/140,510 US14051008A US2009149460A1 US 20090149460 A1 US20090149460 A1 US 20090149460A1 US 14051008 A US14051008 A US 14051008A US 2009149460 A1 US2009149460 A1 US 2009149460A1
Authority
US
United States
Prior art keywords
pyridin
hydroxy
indol
carbonitrile
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/140,510
Inventor
Stefan Berg
Sven Hellberg
Martin Nylof
Yafeng Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/140,510 priority Critical patent/US20090149460A1/en
Publication of US20090149460A1 publication Critical patent/US20090149460A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to new compounds of formula Ia and Ib, as a free base or a pharmaceutically acceptable salt thereof, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
  • the present invention further relates to a process for the preparation of compounds of formula Ia and Ib and to new intermediates used therein.
  • Glycogen synthase kinase 3 is a serine/threonine protein kinase composed of two isoforms ( ⁇ and ⁇ ), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau, ⁇ -catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.
  • eIF2b elongation initiation factor 2b
  • AD dementias Alzheimer's Disease (AD) dementias, and taupathies.
  • AD Alzheimer's disease
  • Glycogen synthase kinase 3 ⁇ (GSK3 ⁇ ) or Tau ( ⁇ ) phosphorylating kinase selectively phosphorylates the microtubule associated protein ⁇ in neurons at sites that are hyperphosphorylated in AD brains.
  • Hyperphosphorylated protein z has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary tangles and neuropil threads in AD brains.
  • Neurofibrillary tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis, parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease.
  • GSK3 ⁇ preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from AD patients.
  • GSK3 ⁇ phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996).
  • Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions.
  • GSK3 ⁇ inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease and other above-referred to diseases.
  • GSK3 ⁇ activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation.
  • the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma.
  • Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3 ⁇ .
  • GSK3 ⁇ inhibitors could be useful in attenuating the course of neurodegenerative diseases.
  • Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3 ⁇ may therefore be of therapeutic relevance in the treatment of BD as well as in AD patients that have affective disorders.
  • GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development.
  • Kozlovsky et al Am J Psychiatry 2000 May; 157(5):831-3
  • GSK3 ⁇ levels were 41% lower in the schizophrenic patients than in comparison subjects.
  • This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia.
  • reduced ⁇ -catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).
  • Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase.
  • GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation.
  • GSK3 is also over-expressed in muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 February; 49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes and diabetic neuropathy.
  • GSK3 phosphorylates and degrades ⁇ -catenin.
  • ⁇ -catenin is an effector of the pathway for keratonin synthesis.
  • ⁇ -catenin stabilisation may be lead to increase hair development.
  • Mice expressing a stabilised ⁇ -catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov. 25; 95 (5):605-14)).
  • the new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis.
  • GSK3 inhibition may offer treatment for baldness.
  • the object of the present invention is to provide compounds having an inhibiting effect on GSK3 as well as having a good bioavailability.
  • P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is nitrogen;
  • R 1 is hydrogen;
  • R 2 and R 3 are independently selected from halogen, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 0-6 alkylC 3-6 cycloalkyl, C 0-6 alkylaryl, C 0-6 alkylheteroaryl, CHO, C 0-6 alkylOR 4 , OC 1-6 alkylOR 4 , C 0-6 alkylSR 4 , OC 1-6 alkylSR 4 , (CO)R 4 , (CO)OR 4 , O(CO)R 4 , fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylcyano, C 0-6 alkylcyan
  • R 7 , R 9 and R 12 each independently are hydrogen or C 1-6 alkyl;
  • R 8 , R 10 , R 11 and R 13 are C 1-6 alkyl;
  • R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W;
  • m is 0, 1, 2, 3 or 4;
  • n is 0, 1, 2, 3 or 4;
  • R 4 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 0-6 alkylC 3-6 cycloalky
  • R 2 and R 3 are independently selected from: halogen, nitro, C 0-6 alkylheteroaryl, trifluoromethyl, C 0-6 alkylcyano, C 0-6 alkylNR 4 R 5 , C 0-6 alkylCONR 4 R 5 , OC 1-6 alkylNR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , and a group X 1 R 6 , wherein X 1 is a direct bond; R 6 is a 5-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, and which heterocyclic group may be substituted with one or two substituents W, preferably C 1-6 alkyl; m is 0, 1, 2; and n is 1 or 2.
  • R 4 is independently selected from hydrogen, C 1-6 alkyl, C 0-6 alkylC 3-6 cycloalkyl, C 0-6 alkylaryl, C 0-6 alkylheteroaryl, C 1-6 alkylNR 14 R 15 and a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;
  • R 5 is selected from hydrogen, C 1-6 alkyl; wherein R 4 and R 5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y; and wherein any C 1-6 alkyl, C 0-6 alkylaryl defined under R 2 to R 5 may be substituted by one or more group Z; R 14 and R 15
  • Yet another aspect of the invention relates to compounds selected from:
  • C 0-6 means a carbon group having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.
  • C 1-6 means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • alkyl includes both straight and branched chain alkyl groups and may be, but is not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.
  • cycloalkyl refers to an optionally substituted, saturated cyclic hydrocarbon ring system.
  • C 3-6 cycloalkyl may be, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • alkylaryl includes both substituted and unsubstituted alkylaryl groups, which may be substituted on the alkyl and/or the aryl and may be, but are not limited to, C 1-6 alkylaryl, benzyl or ethylphenyl.
  • heteroaryl may be a monocyclic heteroaromatic, or a bicyclic fused-ring heteroaromatic group.
  • heteroaryl include, but are not limited to, pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl and triazolyl.
  • alkenyl includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only.
  • alkynyl includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only.
  • the term “5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is selected from nitrogen” includes, but is not limited to, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, imidazolyl.
  • the terms “5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S” or “5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated” or “4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S” may be, but are not limited to, azepanyl, azitidinyl, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, furyl, isoxazolyl, isothiazolyl, oxazo
  • the term “5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S”, includes both aromatic, heteroaromatic rings and heterocyclic rings that are saturated or unsaturated.
  • heterocyclic rings may be, but are not limited to furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl or cyclopentyl.
  • 6-membered heteroaromatic ring containing one or two nitrogen atoms includes, but is not limited to, pyrazinyl, pyridazinyl, pyridyl or pyrimidyl.
  • the term “5-membered heterocyclic group containing one or two heteroatoms atoms, selected independently from N, O and S” includes, but is not limited to, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, thienyl, furyl, imidazolyl, isothiazolyl or isoxazolyl.
  • a subscript is the integer 0 (zero) the group to which the subscript refers to, indicates that the group is absent, i.e. there is a direct bond between the groups.
  • halogen may be fluorine, chlorine, bromine or iodine.
  • the present invention relates to the use of compounds of formula Ia and Ib as hereinbefore defined as well as to the salts thereof.
  • Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula Ia and Ib.
  • compositions of this invention can be employed to form non-toxic pharmaceutically acceptable salts of the compounds of this invention.
  • Pharmaceutically acceptable salts include, but are not limited to hydrochloride, and fumarate. These salts are readily prepared by methods known in the art.
  • Some compounds of formula Ia and Ib may have chiral centres and/or geometric isomeric centres (E- and Z-isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomeric and geometric isomers.
  • a compound of formula Ia or a salt thereof may exhibit the phenomenon of tautomerism as shown in FIG. 1. It is to be understood that the invention encompasses any tautomeric form of compounds of formula Ia and is not to be limited merely to any one tautomeric form utilized within the formula drawings:
  • An object of the invention is to provide compounds of formula Ia or Ib for therapeutic use, especially compounds that are useful for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 (GSK3) in mammals including man. Particularly, compounds of formula Ia or Ib exhibiting a selective affinity for GSK-3.
  • GSK3 glycogen synthase kinase-3
  • a pharmaceutical composition comprising a compound of formula Ia or Ib, as a free base or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
  • the composition may be in a form suitable for oral administration, for example as a tablet, for parenteral injection as a sterile solution or suspension.
  • the above compositions may be prepared in a conventional manner using pharmaceutically carriers or diluents.
  • Suitable daily doses of the compounds of formula Ia or Ib in the treatment of a mammal, including man are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration.
  • the typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.
  • a compound of formula Ia or Ib, or a pharmaceutically acceptable salt thereof can be used on its own but will usually be administered in the form of a pharmaceutical composition in which the formula Ia or Ib compound/salt (active ingredient) is in association with a pharmaceutically acceptable diluent or carrier.
  • the pharmaceutical composition may comprise from 0.05 to 99% w (percent by weight), for example from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
  • a diluent or carrier includes water, aqueous polyethylene glycol, magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methylcellulose, sodium carboxymethyl cellulose or cocoa butter.
  • a composition of the invention can be in tablet or injectable form.
  • the tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).
  • the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a pharmaceutically acceptable salt thereof, a hereinbefore defined, with a pharmaceutically acceptable diluent or carrier.
  • An example of a pharmaceutical composition of the invention is an injectable solution containing a compound of the invention, or a pharmaceutically acceptable salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about pH 5, and optionally a surfactant to aid dissolution.
  • Liquid solution comprising a compound of formula Ia or Ib, or a salt thereof, dissolved in water.
  • the compounds defined in the present invention are well suited for inhibiting glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK-3 in mammals, including man, in need of such prevention and/or treatment.
  • GSK-3 is highly expressed in the central and peripheral nervous system and in other tissues.
  • compounds of the invention are well suited for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system.
  • the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.
  • Other conditions are selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication.
  • Further conditions are selected from the group consisting predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies and androgenetic alopecia.
  • One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.
  • the dose required for the therapeutic or preventive treatment of a particular disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • the present invention relates also to the use of a compound of formula Ia or Ib as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
  • the term “therapy” also includes “prevention” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • the invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula Ia or Ib, as hereinbefore defined.
  • the compounds of formula Ia or Ib as a free base or a pharmaceutically acceptable salt thereof are also useful as pharmacological tools is in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.
  • the present invention also relates to processes for preparing the compound of formula Ia or Ib.
  • suitable protecting groups will be added to, and subsequently removed from the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis.
  • Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are for example described in “Protective Groups in Organic Synthesis”, T. W. Greene, P. G. M Wutz, Wiley-Interscience, New York, 1999.
  • R 2 is halogen
  • halo halogen e.g. bromine, chlorine or iodine
  • a suitable halogenation agent such as Br 2 , Cl 2 , I 2 , ICl, SO 2 Cl 2 or another suitable halogenation agent such as N-bromosuccinimid in an appropriate solvent such as acetonitrile, acetic acid, HCl/ethanol or water, with or without a suitable base e.g. an alkali metal acetate such as sodium acetate, at a reaction temperature between ⁇ 20° C. and room temperature.
  • a suitable tin reagent such as a trialkyltin-R 6 reagent e.g. tributyltin-R 6 in the presence of a suitable catalyst such as bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)palladium(0) or bis(triphenylphosphine)palladium(II) acetate in a suitable solvent such as tetrahydrofuran, acetonitrile, toluene or N,N-dimethylformamide and at a temperature range between 25° C. and reflux.
  • the reaction may be aided by the presence of tetraethyl ammonium chloride.
  • a halogenation reagent such as thionyl chloride or oxalyl chloride in a suitable solvent such as methylene chloride, chloroform or toluene or using the reagent neat and the reaction may occur at a temperature between 0° C.
  • a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile
  • a suitable base such as an alkali metal, an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between ⁇ 20° C.
  • a suitable coupling reagent such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-N,N,N,N′-tetramethyluronium hexafluorophosphate, 1,1′-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate and in a suitable solvent such as methylene chloride, 1,3-diisoprop
  • reaction with the appropriate amine R 4 R 5 NH in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine, the reaction may occur at a temperature between ⁇ 20° C. and +80° C.
  • a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile
  • a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine
  • activation of the sulfonic acid function in the compound of formula XVII with a suitable halogenating reagent such as thionyl chloride or phosphorus oxychloride in a suitable solvent such as methylene chloride, chloroform, acetonitrile or toluene, and sulfolane may be added as a co-solvent to facilitate the reaction.
  • a catalytic amount of N,N-dimethylacetamide may speed up the reaction and the reaction may occur at a temperature between 0° C.
  • a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile
  • a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between ⁇ 20° C. and +80° C.
  • a suitable solvent such as methylene chloride, chloroform, acetonitrile or N,N-dimethylformamide
  • a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between 0° C. and +120° C.
  • a compound of formula XXIV with an appropriate amine R 4 R 5 NH in a suitable solvent such as methylene chloride, chloroform, acetonitrile or N,N-dimethylformamide with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or, an alkylamine base such as triethylamine or, a macroporous polystyrene anion-exchange resin such as MP-Carbonate or, a cross linked polystyrene-co-divinylbenzene such as PS-diisopropylethylamine and the reaction may occur at a temperature between 0° C. and +120° C.
  • a suitable solvent such as methylene chloride, chloroform, acetonitrile or N,N-dimethylformamide
  • a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or, an alkylamine
  • an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • a suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • tetrahydrofuran or 1,4-dioxan an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • a suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • Another object of the invention are processes a, b, c, d and e for the preparation of compounds of general formula Ia and Ib, wherein halo is halogen, P, R 1 , R 2 , R 3 R 4 , R 5 , m and n, unless otherwise specified, are defined as hereinbefore, and salts thereof.
  • These processes comprise; a) reacting a compound of formula B (XV, XVIII, XVIIIa, XXI, XXIII), wherein L 1 is a leaving group such as halogen, e.g. fluorine, chlorine or bromine, with a compound of formula C (e.g. compounds of formula III, V, IX, XII, XIII); wherein R 1 , R 2 and m are as defined as hereinbefore to form a compound of formula Ia;
  • the reaction of process a may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan
  • an aromatic hydrocarbon solvent such as toluene
  • a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • a suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride or, a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between ⁇ 30° C. to +50° C.
  • an acid such as a hydrogen halide such as hydrogen chloride or, a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof.
  • the reaction of process b may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide, the reaction may occur at a temperature between +10° C. and +150° C.
  • an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide
  • a base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • such a base may be an alkali metal hydride such as sodium hydride, an alkali metal or an alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • the N-oxide may be removed by using a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate and the reaction may occur at a temperature between 0° C. and +100° C.
  • a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between ⁇ 30° C. to +50° C.
  • an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid
  • a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof
  • the reaction of process c may be carried out by: i) the reaction of the compound of formula XXVII with the appropriate amine R 4 R 5 NH in a suitable solvent such as benzene, methylene chloride, chloroform, toluene or acetonitrile in the presence of a suitable reagent such as trimethyl aluminum and at a reaction temperature between 0° C.
  • a suitable solvent such as benzene, methylene chloride, chloroform, toluene or acetonitrile
  • a suitable reagent such as trimethyl aluminum
  • reaction may occur at a temperature between ⁇ 20° C. and +150° C.
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between ⁇ 30° C. to +50° C.
  • an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid
  • a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof
  • the N-oxide may be reduced by using a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate and the reaction may occur at a temperature between 0° C. and +100° C.
  • a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between ⁇ 30° C. to +50° C.
  • an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid
  • a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof
  • reaction of process e may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan or mixtures thereof in the presence of a suitable fluorinating reagent such as 1-fluoro-2,4,6-trimethylpyridinium triflate and a suitable base such as n-butyllithium or sodium bis(trimethylsilyl)amide and at a reaction temperature between ⁇ 40° C. and +80° C.
  • an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan or mixtures thereof
  • a suitable fluorinating reagent such as 1-fluoro-2,4,6-trimethylpyridinium triflate
  • a suitable base such as n-butyllithium or sodium bis(trimethylsilyl)amide
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between ⁇ 30° C. to +50° C.
  • an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid
  • a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof
  • the present invention further relates to new intermediates and the use of these intermediates in the preparation of compounds of formula Ia and Ib as defined hereinbefore.
  • the intermediate is a compound according to formula XXV
  • halo is halogen
  • R 3 is selected from halogen, nitro, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylNR 4 R 5 , C 0-6 alkylcyano, C 0-6 alkylCONR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , C 0-6 alkylNR 4 R 5 and a group X 1 R 6 , wherein X is a direct bond, O, CONR 7 R 8 , SO 2 NR 9 R 10 , SO 2 R 11 or NR 12 R 13 ; R 7 , R 9 and R 12 each independently are hydrogen or C 1-3 alkyl; R 8 , R 10 , R 11 and R 13 are C 0-4 alkyl; R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two hetero
  • the intermediate is a compound according to formula B (XV, XVIII, XVIIIa XXI, XXIII)
  • P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is selected from nitrogen and L 1 is a leaving group such as a halogen e.g.
  • R 3 is selected from halogen, nitro, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylNR 4 R 5 , C 0-6 alkylcyano, C 0-6 alkylCONR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , C 0-6 alkylNR 4 R 5 and a group X 1 R 6 , wherein X 1 is a direct bond, O, CONR 7 R 8 , SO 2 NR 9 R 10 , SO 2 R 11 or NR 12 R 13 ; R 7 , R 9 and R 12 each independently are hydrogen or C 1-3 alkyl; R 8 , R 10 , R 11 and R 13 are C 0-4 alkyl; R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or
  • the intermediate is a compound according to formula C (III, V, IX, XII, XIII)
  • R 1 is hydrogen
  • R 2 is selected from halogen, nitro, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylNR 4 R 5 , C 0-6 alkylcyano, C 0-6 alkylCONR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , C 0-6 alkylNR 4 R 5 and a group X 1 R 6 , wherein X 1 is a direct bond, O, CONR 7 R 8 , SO 2 NR 9 R 10 , SO 2 R 11 or NR 12 R 13 ; R 7 , R 9 and R 12 each independently are hydrogen or C 1-3 alkyl; R 8 , R 10 , R 11 and R 13 are C 0-4 alkyl; R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms
  • R 1 is hydrogen
  • R 2 is selected from halogen and a group X 1 R 6 , wherein X 1 is a direct bond
  • R 6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S
  • m is 1 or 2.
  • the intermediate is a compound according to formula XXVII
  • R 1 is hydrogen
  • R 2 is selected from halogen, nitro, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylNR 4 R 5 , C 0-6 alkylcyano, C 0-6 alkylCONR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , C 0-6 alkylNR 4 R 5 and a group X 1 R 6 , wherein X is a direct bond, O, CONR 7 R 8 , SO 2 NR 9 R 10 , SO 2 R 11 or NR 12 R 13 ; R 7 , R 9 and R 12 each independently are hydrogen or C 1-3 alkyl; R 8 , R 10 , R 11 and R 13 are C 0-4 alkyl; R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms,
  • the intermediate is a compound according to formula XXVIII
  • R 1 is hydrogen
  • R 2 is selected from halogen, nitro, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC 1-6 alkylNR 4 R 5 , C 0-6 alkylcyano, C 0-6 alkylCONR 4 R 5 , C 0-6 alkyl(SO 2 )NR 4 R 5 , C 0-6 alkylNR 4 R 5 and a group X 1 R 6 , wherein X 1 is a direct bond, O, CONR 7 R 8 , SO 2 NR 9 R 10 , SO 2 R 11 or NR 12 R 13 ; R 7 , R 9 and R 12 each independently are hydrogen or C 1-3 alkyl; R 8 , R 10 , R 11 and R 13 are C 0-4 alkyl; R 6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms
  • R 1 is hydrogen
  • R 2 is a group X 1 R 6 , wherein X 1 is a direct bond
  • R 6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S
  • m is 1
  • a further aspect of the invention relates to use of the compounds according to any one of formulas XXV; B (XV, XVIII, XVIIIa XXI, XXIII); C (III, V, IX, XII, XIII); XXVII; XXVIII; in the preparation of a compound of formula Ia or Ib.
  • temperatures are given in degrees Celsius (° C.); operations were carried out at room temperature, i.e. at a temperature in the range of 18 to 25° C.;
  • yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
  • NMR data is in the form of delta values, given in parts per million (ppm) relative to the solvent or relative to tetramethylsilane (TMS) as an internal standard;
  • chemical symbols have their usual meanings; SI units and symbols are used;
  • solvent ratios are given in volume:volume (v/v) terms; and
  • mass spectra where indicated, ionization was effected by chemical ionization (CI), electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP) unless otherwise indicated; values for m/z are given; generally, only ions which indicate the parent mass are reported.
  • the title compound was prepared as described for Example 1 using 2-chloroisonicotinic acid and 1-methylpiperazine.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc. NH 3 (aq), (100:10:1), as the eluent to give the title compound as a colorless oil.
  • N-(2-hydroxyethyl)morpholine (1.09 g, 8.27 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (364 mg, 9.10 mmol, 60% dispersion in oil) in portions.
  • the mixture was stirred at room temperature for 1 h and at 45° C. for 1.5 h.
  • the greenish solution was added dropwise over 5 min to a solution of 4,6-dichloropyrimidine (3.0 g, 20.1 mmol) in N,N-dimethylformamide (5 mL).
  • the solvent was removed in vacuo, and the residue was partitioned between water and ethyl acetate.
  • PS-Diisopropylethylamine (3.54 mmol/g, 0.4 g, 1.40 mmol) was washed with tetrahydrofuran and 2-chloro-5-(chloromethyl)pyridine 1-oxide (100 mg, 0.56 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) was added followed by tetrahydrofuran (1 mL).
  • the suspension was filtered (20 ⁇ m polyethylene filter), and the resins were washed with methylene chloride, tetrahydrofuran, and ethanol. Volatiles were removed in vacuo, and the residue was suspended in a 1:1-mixture of tetrahydrofuran and ethanol (8 mL) followed by the addition of N-ethyl-N,N-diisopropylamine (50 ⁇ L, 0.28 mmol). The mixture was added to PS-Thiophenol (1.35 mmol/g, 0.21 g, 0.28 mmol), and MP-Carbonate (3.20 mmol/g, 90 mg, 0.28 mmol), both pre-swelled in tetrahydrofuran.
  • PS-Diisopropylethylamine (3.54 mmol/g, 0.4 g, 1.40 mmol) was washed with tetrahydrofuran and 2-chloro-5-(chloromethyl)pyridine 1-oxide (100 mg, 0.56 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) was added followed by tetrahydrofuran (1 mL).
  • a solution of 3-methylpiperidine in tetrahydrofuran (1.5 mL) and a catalytic amount of potassium iodide were added, and the mixture was gently stirred (80 r/min) at room temperature for 5 days.
  • PS-Isocyanate (1.10 mmol/g, 1.27 g, 1.40 mmol) was washed with tetrahydrofuran and added to the mixture followed by additional tetrahydrofuran (2 mL). The suspension was gently stirred (80 r/min) at room temperature overnight. N-Ethyl-N,N-diisopropylamine (50 ⁇ L, 0.28 mmol) and MP-Carbonate (2.55 mmol/g, 0.66 g, 1.68 mmol) were added, and the contents were mixed and gently stirred for 24 h. The mixture was filtered (20 ⁇ m polyethylene filter), and the resins were washed with methylene chloride. Volatiles were removed in vacuo to give 138 mg (99% yield) of the title compound: MS (ES) m/z 241 (M + +1).
  • 6-Bromooxindole (0.168 g, 0.8 mmol) was dissolved in acetic acid (4 mL) and stirred for 5 min at room temperature. N-Bromosuccinimide (0.14 g, 0.8 mmol) was added and the yellow reaction mixture was stirred for 3 h at ambient temperature. The mixture was poured onto ice and the resulting precipitate was collected by filtration and dried in vacuo to give 0.192 g (83% yield) of the title compound as a white solid: 1 H NMR (DMSO-d6, 400 MHz) ⁇ 10.61 (s, 1H), 7.60 (s, 1H), 7.14 (s, 1H), 3.52 (s, 2H).
  • reaction was quenched with water (10 mL) and an aqueous saturated ammonium chloride solution (30 mL) and extracted with ethyl acetate. The combined organic phases were dried (Na 2 SO 4 ) and evaporated in vacuo.
  • This batch was combined with an new batch starting from 230 mg of 5-(chloroacetyl)-1,3-dihydro-2H-indol-2-one and the combined reaction mixtures was concentrated to approximately 10 mL and an aqueous saturated sodium hydrogencarbonate solution (50 mL) was added and the solution was extracted with ethyl acetate. The combined organic layers were dried (Na 2 SO 4 ) and evaporated in vacuo.
  • the solvent was removed in vacuo, and the residue was partitioned between chloroform and water. The phases were separated and the pH of the water phases was adjusted to 8 with a 2 M aqueous solution of HCl. The aqueous layer was extracted with ethyl acetate and the organic layers were dried (Na 2 SO 4 ), combined, and the solvent was removed in vacuo affording an orange semi-solid.
  • the base was dissolved in a mixture of methanol, dichloromethane, and ethyl acetate (15 mL total volume) and cooled on ice. A solution of HCl in diethyl ether (1 M) was added until acidic pH. Approximately half of the solvent volume was removed in vacuo, and ethyl acetate was added. The precipitated hydrochloride salt was filtered, washed with ethyl acetate, and dried in vacuo at 40° C.
  • the aqueous layer was alkalized to pH 8 by adding a 45% aqueous NaOH solution.
  • the obtained suspension was extracted twice with ethyl acetate.
  • the combined phases were washed with brine, dried (Na 2 SO 4 ) and the solvent was removed in vacuo.
  • the aqueous layer was alkalized with NaHCO 3 (s) until saturation followed by three extractions with ethyl acetate.
  • the organic layers were combined, dried (Na 2 SO 4 ), and the solvent was removed in vacuo.
  • the obtained material was purified twice by column chromatography on silica using chloroform/methanol/conc. NH 3 (aq), (90:10:0.5), as the eluent affording 56 mg of an oil.
  • the organic layer was extracted with 2 M HCl(aq).
  • the combined aqueous layers were alkalized to saturation with NaHCO 3 (s), and extracted two times with ethyl acetate.
  • the extracts were combined, dried (Na 2 SO 4 ) and the solvent was removed in vacuo to give 270 mg of a crude product.
  • the material was dissolved in ethyl acetate (15 mL), and a solution of phosphorus trichloride (0.25 mL, 2.87 mmol) in ethyl acetate (3 mL) was added. An orange precipitate was immediately formed. The mixture was heated at reflux for 30 min, and was then allowed to cool.
  • the base (65 mg) was dissolved in a mixture of ethyl acetate (20 mL), methylene chloride (10 mL), and methanol (2 mL), and was then cooled on an ice-bath. A solution of HCl in diethyl ether (1 M) was added until acidic pH. About 60% of the solvent volume was evaporated and to the residual suspension was added ethyl acetate. The obtained orange hydrochloride was filtered, washed with ethyl acetate, and dried in vacuo at 40° C.
  • Example 60 The following Examples, 61-62, were prepared as described for Example 60:
  • the base (72 mg) was dissolved in a mixture of ethyl acetate (5 mL), methylene chloride (10 mL), and was then cooled on an ice-bath. A solution of HCl in diethyl ether was (1 M) added until acidic pH.
  • the obtained precipitate was partitioned between a saturated aqueous NaHCO 3 solution and ethyl acetate.
  • the aqueous layer was extracted with another two portions of ethyl acetate.
  • the combined organic layers were dried (Na 2 SO 4 ), and the solvent was removed in vacuo affording a crude product.
  • the material was dissolved in ethyl acetate (25 mL), and phosphorus trichloride (0.24 mL, 2.71 mmol) was added. An orange precipitate was immediately formed.
  • the mixture was heated at reflux for 30 min, and was then allowed to cool.
  • the mixture was partitioned between ethyl acetate and a saturated aqueous NaHCO 3 solution.
  • the aqueous layer was neutralized with 45% NaOH(aq) and alkalized to saturation with NaHCO 3 (s), and extracted two times with ethyl acetate.
  • the extracts were combined, dried (MgSO 4 ) and the solvent was removed in vacuo affording 84 mg of the crude product.
  • the material was dissolved in ethyl acetate (10 mL), and to the solution was added phosphorus trichloride (0.2 mL, 2.24 mmol).
  • the obtained orange suspension was heated at reflux for 1 h and was then allowed to cool.
  • the precipitate was filtered, washed with ethyl acetate, and dried in vacuo affording 70 mg of an orange residue.
  • Example 72 The following Examples, 72-73, were prepared as described for Example 71:
  • the mixture was extracted twice with methylene chloride and the combined organic layers were dried (Na 2 SO 4 ), filtrated and the solvent was removed in vacuo.
  • the residue was purified on a silica gel column using a gradient ethyl acetate/methanol, (40:1 to 1:1), as the eluent.
  • the product was dissolved in a mixture of methylene chloride (5 mL) and methanol (5 mL). Hydrogen chloride (3 mL, 1 M in diethyl ether) was added and stirring was continued for 10 min.
  • the title compound was prepared as described for Example 74 using 6-chlorooxindole.
  • the base was purified on a silica gel column using a gradient chloroform/methanol, (100:0 to 4:1), as the eluent.
  • the product was dissolved in a mixture of chloroform (10 mL) and methanol (10 mL). Hydrogen chloride (3 mL, 1 M in diethyl ether) was added and stirring was continued for 10 min.
  • Ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (0.327 g, 1.0 mmol) was suspended in benzene (13 mL) followed by the addition of morpholine (0.218 g, 2.5 mmol). The mixture was stirred (N2 atmosphere) for 5 min at 0° C. To this mixture, trimethyl aluminum (2 M solution in hexane, 2 mL, 4 mmol) was added via a syringe. After 10 min the temperature was raised to 70° C. and the reaction mixture was stirred for 20 h then poured onto an ice-cold aqueous saturated NaHCO 3 solution and extracted with chloroform.
  • the solvent was evaporated in vacuo and the residual oil was purified on a silica gel column using chloroform/methanol, (10:1), as eluent affording the N-oxide product.
  • the N-oxide was dissolved in chloroform (3 mL) and phosphorus trichloride (0.412 g, 3.0 mmol) was added.
  • the reaction mixture was stirred for 30 min at 60° C. and then cooled to room temperature. The mixture was quenched with methanol and concentrated.
  • the residue was purified on a silica column using a chloroform/methanol gradient, (10:1 to 1:2), as the eluent to give 52 mg (4% yield) of the title compound as the base as brownish solid.
  • the title compound was prepared as described for Example 77 using 6-cyanooxindole.
  • the base was obtained as a yellow solid after purification by preparative HPLC (column: Xterra, C 8 , 7 ⁇ m, 19 ⁇ 300 mm; eluent: 0.1 M NH 4 OAc buffer/acetonitrile, 8:2 to 4:6). Yield: 13%.
  • the N,N-dimethylformamide solution was diluted with an aqueous saturated NaHCO 3 solution and NaCl (s, 2 g) was added followed by extraction with chloroform and ethyl acetate. The combined organic phases were dried (Na 2 SO 4 ) and concentrated in vacuo. The remaining N,N-dimethylformamide was removed by co-evaporation with toluene two times. The residual oil was dissolved in chloroform (10 mL) and phosphorus trichloride (3.0 g, 21.8 mmol) was added. The reaction mixture was stirred for 30 min at 60° C. and then cooled to room temperature. The mixture was poured into an aqueous saturated NaHCO 3 solution.
  • the brown solid was dissolved in methanol (150 mL) and insoluble materials were removed by filtration. This solution was concentrated to a brownish yellow solid, which was suspended in ethyl acetate (15 mL) and stirred overnight at room temperature. The yellow solid was collected by filtration and dried to afford 1.28 g of the product.
  • the title compound was prepared as described for Example 79 using 5,6-dibrom-1,3-dihydro-indol-2-one.
  • the base (27% yield) was transformed to the hydrochloride salt.
  • the salt was purified by re-crystallization from chloroform/methanol/diethyl ether and the crystals were washed with dimethylsulfoxide (1 mL) to give the title compound.
  • the title compound was prepared as described for Example 86 using 3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol and phosphorus trichloride.
  • the base was dissolved in chloroform/methanol, (3:1), and a solution of HCl in diethyl ether (1 M) was added until acidic pH. The formed precipitation was filtered, washed with diethyl ether and dried.
  • the title compound was prepared as described for Example 55 using 6-cyanooxindole (1.5 equ) and 1-(6-chloropyridine-3-sulfonyl)-4-methylpiperazine (1 equ; described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203). Purification on a silica gel column using chloroform/methanol/conc. NH 3 (aq), (76:23:1), as the eluent gave the title compound as the base. The base was dissolved in acetone/chloroform/methanol and treated with 5 M HCl in diethyl ether.
  • the title compound was prepared as described for Example 92 using ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (1 eqv), trimethyl aluminium (4 eqv), N-methylpipearzine (2 eqv) and benzene as the solvent.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:12:1.2), as the eluent. Yield: 69% of the title compound as the base.
  • the base was converted to the fumarate salt according to the procedure described for Example 103: MS (ES) m/z 382 (M + +1).
  • the title compound was prepared as described for Example 101 using 6-chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide and 5-cyanooxindole.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:10:1), as the eluent followed by another purification on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:7:0.7), as the eluent.
  • the base was converted to the fumarate salt according to the procedure described for Example 103: Yield: 20%: MS (ES) m/z 386 (M + +1).
  • the title compound was prepared as described for Example 101 using 6-chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide and 5-cyanooxindole.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:10:1), as the eluent: MS (ES) m/z 414 (M + +1).
  • the base was dissolved in chloroform (15 mL) and methanol (2 mL) and fumaric acid dissolved in methanol (2 mL) was added. Diethyl ether (20 mL) was added and the formed precipitate was filtered and dried to give the title compound. Yield: 10%: MS (ES) m/z 414 (M + +1).
  • the title compound was prepared as described for Example 101 using 6-chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide and 5-cyanooxindole.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:18:1.8), as the eluent. Yield: 50%: MS (ES) m/z 426 (M + +1).
  • the base was converted to the fumarate salt according to the procedure described for Example 103.
  • the title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane and 5-cyanooxindole.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:15:1.5), as the eluent. Yield: 50%: MS (ES) m/z 412 (M + +1).
  • the base was converted to the fumarate salt according to the procedure described for Example 103.
  • the title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) and 5-(2-methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (50:3:0.3), as the eluent.
  • the base was dissolved in chloroform/methanol and converted to the hydrochloride salt using HCl in diethyl ether (1 M). Yield: 35% of the title compound: MS (ES) m/z 470 (M + +1).
  • the title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) and 5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one.
  • the crude product was purified on a silica gel column using chloroform/methanol/conc NH 3 (aq), (100:10:1), as the eluent followed by trituration in ethyl acetate. Yield: 1% of the title compound: MS (ES) m/z 441 (M + +1).
  • the solvent was removed in vacuo and the residual oil was purified on a silica gel column using chloroform/methanol, (10:1) as the eluent affording the N-oxide product.
  • the N-oxide was dissolved in chloroform (2 mL) and phosphorous trichloride (0.385 g, 2.80 mmol) was added. The reaction mixture was stirred for 30 min at 60° C. followed by extraction with an aqueous saturated NaHCO 3 solution.
  • the organic layer was dried (Na 2 SO 4 ) and concentrated to a yellowish red oil which was purified on a silica gel column using chloroform/methanol, (10:1) as the eluent to give 10 mg (4% yield) of the title compound as the free base as an yellow solid.
  • the base (10 mg, 0.028 mmol) was dissolved in methylene chloride/methanol, (1:1) and treated with 1 M HCl in diethyl ether at 0° C.
  • the reaction was initiated by the addition of 0.04 ⁇ Ci [ ⁇ - 33 P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1 ⁇ M and assay volume of 25 ⁇ l. After incubation for 20 minutes at room temperature, each reaction was terminated by the addition of 25 ⁇ l stop solution containing 5 mM EDTA, 50 ⁇ M ATP, 0.1% Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham, UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The K m value of ATP for GSK3 ⁇ , used to calculate the inhibition constants (K i ) of the various compounds, was 20 ⁇ M.
  • GSK3 Glycogen synthase kinase 3 MP-Carbonate Macroporous triethylamonium methylpolystyrene carbonate
  • Typical K i values for the compounds of the present invention are in the range of about 0.001 to about 10,000 nM. Other values for K i are in the range of about 0.001 to about 1000 nM. Further values for K i are in the range of about 0.010 nM to about 300 nM.

Abstract

The present invention provides new compounds of formula Ia and Ib:
Figure US20090149460A1-20090611-C00001
as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

Description

    FIELD OF THE INVENTION
  • The present invention relates to new compounds of formula Ia and Ib, as a free base or a pharmaceutically acceptable salt thereof, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. The present invention further relates to a process for the preparation of compounds of formula Ia and Ib and to new intermediates used therein.
    • BACKGROUND OF THE INVENTION
  • Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase composed of two isoforms (α and β), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau, β-catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.
  • Alzheimer's Disease (AD) dementias, and taupathies.
  • AD is characterized by cognitive decline, cholinergic dysfunction and neuronal death, neurofibrillary tangles and senile plaques consisting of amyloid-β deposits. The sequence of these events in AD is unclear, but are believed to be related. Glycogen synthase kinase 3β (GSK3β) or Tau (τ) phosphorylating kinase selectively phosphorylates the microtubule associated protein τ in neurons at sites that are hyperphosphorylated in AD brains. Hyperphosphorylated protein z has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary tangles and neuropil threads in AD brains. This results in depolymerization of microtubules, which leads to dying back of axons and neuritic dystrophy. Neurofibrillary tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis, parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease. Addition of amyloid-O to primary hippocampal cultures results in hyperphosphorylation of τ and a paired helical filaments-like state via induction of GSK3β activity, followed by disruption of axonal transport and neuronal death (Imahori and Uchida., J. Biochem 121:179-188, 1997). GSK3β preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from AD patients. Furthermore, GSK3β phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996). Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions. Thus, GSK3β inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease and other above-referred to diseases.
    • Chronic and Acute Neurodegenerative Diseases.
  • Growth factor mediated activation of the PI3K/Akt pathway has been shown to play a key role in neuronal survival. The activation of this pathway results in GSK3β inhibition. Recent studies (Bhat et. al., PNAS 97:11074-11079 (2000)) indicate that GSK3β activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation. For example, the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma. Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3β. Thus GSK3β inhibitors could be useful in attenuating the course of neurodegenerative diseases.
    • Bipolar Disorders (BD)
  • Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3β may therefore be of therapeutic relevance in the treatment of BD as well as in AD patients that have affective disorders.
    • Schizophrenia
  • GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development. Kozlovsky et al (Am J Psychiatry 2000 May; 157(5):831-3) found that GSK3β levels were 41% lower in the schizophrenic patients than in comparison subjects. This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia. Furthermore, reduced β-catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).
    • Diabetes
  • Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase. Under resting conditions, GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation. GSK3 is also over-expressed in muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 February; 49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes and diabetic neuropathy.
    • Hair Loss
  • GSK3 phosphorylates and degrades β-catenin. β-catenin is an effector of the pathway for keratonin synthesis. β-catenin stabilisation may be lead to increase hair development. Mice expressing a stabilised β-catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov. 25; 95 (5):605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.
    • Oral Contraceptives
  • Vijajaraghavan et al. (Biol Reprod 2000 June; 62 (6):1647-54) reported that GSK3 is high in motile versus immotile sperm. Immunocytochemistry revealed that GSK3 is present in the flagellum and the anterior portion of the sperm head. These data suggest that GSK3 could be a key element underlying motility initiation in the epididymis and regulation of mature sperm function. Inhibitors of GSK3 could be useful as contraceptives for males.
    • DISCLOSURE OF THE INVENTION
  • The object of the present invention is to provide compounds having an inhibiting effect on GSK3 as well as having a good bioavailability.
  • Accordingly, the present invention provides compounds of formula Ia and Ib:
  • Figure US20090149460A1-20090611-C00002
  • wherein:
    P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is nitrogen;
    R1 is hydrogen;
    R2 and R3 are independently selected from halogen, nitro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl, CHO, C0-6alkylOR4, OC1-6alkylOR4, C0-6alkylSR4, OC1-6alkylSR4, (CO)R4, (CO)OR4, O(CO)R4, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylcyano, C0-6alkylcyano, C1-6alkylCO2R4, OC1-6alkylCO2R4, O(CO)OR4, OC1-6alkylCOR4, C1-6alkylCOR4, NR4OR5, C0-6alkylNR4R5, OC1-6alkylNR4R5, C0-6alkylCONR4R5, OC1-6alkylCONR4R5, OC1-6alkylNR4(CO)R5, C0-6alkylNR4(CO)R5, C0-6alkylNR4(CO)NR4R5, O(CO)NR4R5, NR4(CO)OR5, C0-6alkyl(SO2)NR4R5, OC1-6alkyl(SO2)NR4R5, C0-6alkylNR4(SO2)R5, OC1-6alkylNR4(SO2)R5, C0-6alkyl(SO)NR4R5, OC1-6alkyl(SO)NR4R5, SO3R4, C0-6alkylNR4(SO2)NR4R5, C0-6alkylNR4(SO)R5, OC0-6alkylNR4(SO)R5, OC0-6alkylSO2R4, C0-6alkylSO2R4, C0-6alkylSOR4, OC1-6alkylSOR4 and a group X1R6, wherein X1 is a direct bond, O, CONR7R8, SO2NR9R10, SO2R1 or NR12R13; and wherein R6 is linked to
    • R8, R10, R11 and R13;
  • R7, R9 and R12 each independently are hydrogen or C1-6alkyl;
    R8, R10, R11 and R13 are C1-6alkyl;
    R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W;
    m is 0, 1, 2, 3 or 4;
    n is 0, 1, 2, 3 or 4;
    R4 is selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl, C1-6alkylNR14R15 and a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;
    R5 is selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl and C1-6alkylNR14R15 and; wherein R4 and R5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted is by a group Y; and wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl; and C0-6alkylheteroaryl defined under R2 to R5 may be substituted by one or more group Z;
    R14 and R15 are independently selected from hydrogen, C1-6alkyl and C0-6alkylC3-6cycloalkyl and wherein R14 and R15 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;
    W and Z are independently selected from oxo, halogen, nitro, CN, OR16, C1-6alkyl, C0-6alkylaryl, C0-6alkylC3-6cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR16R17, NR16R17, CONR16R17NR16(CO)R17, O(CO)C1-6alkyl, (CO)OC1-6alkyl, COR16, (SO2)NR16R17, SO2R16, SOR16, (CO)C1-6alkylNR16R17, (SO2)C1-6alkylNR16R17, a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, phenyl and heteroaryl, which heterocyclic group, phenyl or heteroaryl may optionally be substituted by a group Y;
    Y is selected from oxo, halogen, nitro, CN, OR16, C1-6alkyl, C0-6alkylaryl, C0-6alkylC3-6cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR16R17, NR16R17, CONR16R17, NR16(CO)R17, O(CO)C1-6alkyl, (CO)OC1-6alkyl, COR16, (SO2)NR16R17, SO2R16, SOR16, (CO)C1-6alkylNR16R71 (SO2)C1-16alkylNR16R17, phenyl, C0-6alkylaryl and heteroaryl wherein the phenyl, C0-6alkylaryl and heteroaryl group may be optionally substituted with halogen, nitro, CN, OR16, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy and trifluoromethoxy;
    R16 and R17 are independently selected from hydrogen and C1-6alkyl and wherein R16, and R17 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S;
    as a free base or a pharmaceutically acceptable salt thereof.
  • In one aspect of the invention there is provided compounds of Formula Ia and Ib wherein P is a 6-membered heteroaromatic ring containing one or two nitrogen atoms.
  • In a first embodiment of this aspect of the invention there is provided compounds of Formula Ia and Ib, wherein P is pyridine.
  • In another embodiment of this aspect of the invention there is provided compounds of is Formula Ia and Ib, wherein P is pyrimidine.
  • In another aspect of the invention there is provided compounds of Formula Ia.
  • In yet another aspect of the invention there is provided compounds of Formula Ia and Ib wherein R2 and R3 are independently selected from: halogen, nitro, C0-6alkylheteroaryl, trifluoromethyl, C0-6alkylcyano, C0-6alkylNR4R5, C0-6alkylCONR4R5, OC1-6alkylNR4R5, C0-6alkyl(SO2)NR4R5, and a group X1R6, wherein X1 is a direct bond; R6 is a 5-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, and which heterocyclic group may be substituted with one or two substituents W, preferably C1-6alkyl; m is 0, 1, 2; and n is 1 or 2.
  • In yet another aspect of the invention there is provided compounds of Formula Ia and Ib wherein R4 is independently selected from hydrogen, C1-6alkyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl, C1-6alkylNR14R15 and a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y; R5 is selected from hydrogen, C1-6alkyl; wherein R4 and R5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y; and wherein any C1-6alkyl, C0-6alkylaryl defined under R2 to R5 may be substituted by one or more group Z; R14 and R15 are independently C1-6alkyl and wherein R14 and R15 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S; Z is independently selected from, halogen, C1-6alkyl, CN, NR16R17; Y is selected from C1-6alkyl, C0-6alkylaryl, NR16R17, phenyl, wherein the phenyl may be optionally substituted with nitro and trifluoromethyl; R16 and R17 are C1-6alkyl and wherein R16 and R17 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S.
  • In yet another aspect of the invention there is provided compounds of Formula Ia and Ib wherein P is pyridine; R1 is hydrogen; R2 is CN; R3 is C0-6alkylNR4R5; wherein R4 and R5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S.
  • Yet another aspect of the invention relates to compounds selected from:
    • 2-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]isonicotinamide;
    • 2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride;
    • 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;
    • 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-{5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
    • 3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-[5-({4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
    • 3-(5-{[(2-Cyanoethyl)(ethyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
    • 3-(5-{[(4-Chlorobenzyl)(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
    • 3-(5-{[(2-Furylmethyl)(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-(5-{[methyl(phenyl)amino]methyl}pyridin-2-yl)-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-{5-[(3-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
    • 3-(5-{[Cyclohexyl(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
    • 2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
    • 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol hydrochloride;
    • 6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol hydrochloride;
    • 3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol;
    • 6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride;
    • 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride;
    • 5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride;
    • 5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride;
    • 3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile hydrochloride;
    • 3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-(5-{[4-(3-methylbutyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1H-indole-5-carbonitrile hydrochloride;
    • 2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile hydrochloride;
    • 3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile hydrochloride;
    • 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol;
    • 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol hydrochloride;
    • 5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol hydrochloride;
    • 3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1H-indol-2-ol hydrochloride;
    • 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol hydrochloride;
    • 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-6-carbonitrile hydrochloride;
    • N-[(1-Ethylpyrrolidin-2-yl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride;
    • 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)nicotinamide hydrochloride;
    • 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)nicotinamide hydrochloride;
    • 5-Nitro-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]pyridin-2-yl}-1H-indol-2-ol hydrochloride;
    • 3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1H-indol-2-ol hydrochloride;
    • N-[2-(Dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide hydrochloride;
    • 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-(2-pyrollindin-1-ylethyl)nicotinamide fumarate;
    • 3-{5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-5-nitro-1H-indol-2-ol fumarate;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)nicotinamide fumarate;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide fumarate;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide fumarate;
    • 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide fumarate;
    • 2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile fumarate;
    • 2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
    • 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1H-indol-2-ol hydrochloride;
    • 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-thiazol-4-yl)-1H-indol-2-ol fumarate;
    • 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-oxazol-5-yl)-1H-indol-2-ol;
    • 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride.
  • Listed below are definitions of various terms used in the specification and claims to describe the present invention.
  • For the avoidance of doubt it is to be understood that where in this specification a group is qualified by ‘hereinbefore defined’, ‘defined hereinbefore’ or ‘defined above’ the said group encompasses the first occurring and broadest definition as well as each and all of the other definitions for that group.
  • For the avoidance of doubt it is to be understood that in this specification ‘C0-6’ means a carbon group having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.
  • For the avoidance of doubt it is to be understood that in this specification ‘C1-6’ means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • In this specification, unless stated otherwise, the term “alkyl” includes both straight and branched chain alkyl groups and may be, but is not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.
  • In this specification, unless stated otherwise, the term “cycloalkyl” refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term “C3-6cycloalkyl” may be, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • In this specification, unless stated otherwise, the term “alkylaryl”, includes both substituted and unsubstituted alkylaryl groups, which may be substituted on the alkyl and/or the aryl and may be, but are not limited to, C1-6alkylaryl, benzyl or ethylphenyl.
  • In this specification, unless stated otherwise, the term “heteroaryl” may be a monocyclic heteroaromatic, or a bicyclic fused-ring heteroaromatic group. Examples of said heteroaryl include, but are not limited to, pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl and triazolyl.
  • In this specification, unless stated otherwise, the term “alkenyl” includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only. The term C2-C6 alkenyl having 2 to 6 carbon atoms and one or two double bonds, and may be, but is not limited to, vinyl, allyl, propenyl, i-propenyl, butenyl, i-butenyl, crotyl, pentenyl, i-pentenyl or hexenyl.
  • In this specification, unless stated otherwise, the term “alkynyl” includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only. The term C2-C6 alkynyl having 2 to 6 carbon atoms and one or two triple bonds, and may be, but is not limited to, etynyl, propargyl, butynyl, i-butynyl, pentynyl, i-pentynyl or hexynyl.
  • In this specification, unless stated otherwise, the term “5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is selected from nitrogen” includes, but is not limited to, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, imidazolyl.
  • In this specification, unless stated otherwise, the terms “5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S” or “5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated” or “4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S” may be, but are not limited to, azepanyl, azitidinyl, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl.
  • In this specification, unless stated otherwise, the term “5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S”, includes both aromatic, heteroaromatic rings and heterocyclic rings that are saturated or unsaturated. Examples of such heterocyclic rings may be, but are not limited to furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl or cyclopentyl.
  • In this specification, unless stated otherwise, the term “6-membered heteroaromatic ring containing one or two nitrogen atoms” includes, but is not limited to, pyrazinyl, pyridazinyl, pyridyl or pyrimidyl.
  • In this specification, unless stated otherwise, the term “5-membered heterocyclic group containing one or two heteroatoms atoms, selected independently from N, O and S” includes, but is not limited to, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, thienyl, furyl, imidazolyl, isothiazolyl or isoxazolyl.
  • In the case where a subscript is the integer 0 (zero) the group to which the subscript refers to, indicates that the group is absent, i.e. there is a direct bond between the groups.
  • In this specification, unless stated otherwise, the term halogen may be fluorine, chlorine, bromine or iodine.
  • The present invention relates to the use of compounds of formula Ia and Ib as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula Ia and Ib.
  • Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable salts of the compounds of this invention. Pharmaceutically acceptable salts include, but are not limited to hydrochloride, and fumarate. These salts are readily prepared by methods known in the art.
  • Some compounds of formula Ia and Ib may have chiral centres and/or geometric isomeric centres (E- and Z-isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomeric and geometric isomers.
  • Within the present invention it is to be understood that a compound of formula Ia or a salt thereof may exhibit the phenomenon of tautomerism as shown in FIG. 1. It is to be understood that the invention encompasses any tautomeric form of compounds of formula Ia and is not to be limited merely to any one tautomeric form utilized within the formula drawings:
  • Figure US20090149460A1-20090611-C00003
  • wherein P, R1, R2, R3, m and n are as defined above.
  • An object of the invention is to provide compounds of formula Ia or Ib for therapeutic use, especially compounds that are useful for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 (GSK3) in mammals including man. Particularly, compounds of formula Ia or Ib exhibiting a selective affinity for GSK-3.
    • Pharmaceutical Compositions
  • According to one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula Ia or Ib, as a free base or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
  • The composition may be in a form suitable for oral administration, for example as a tablet, for parenteral injection as a sterile solution or suspension. In general the above compositions may be prepared in a conventional manner using pharmaceutically carriers or diluents. Suitable daily doses of the compounds of formula Ia or Ib in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.
  • A compound of formula Ia or Ib, or a pharmaceutically acceptable salt thereof, can be used on its own but will usually be administered in the form of a pharmaceutical composition in which the formula Ia or Ib compound/salt (active ingredient) is in association with a pharmaceutically acceptable diluent or carrier. Dependent on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99% w (percent by weight), for example from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
  • A diluent or carrier includes water, aqueous polyethylene glycol, magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methylcellulose, sodium carboxymethyl cellulose or cocoa butter.
  • A composition of the invention can be in tablet or injectable form. The tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).
  • The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a pharmaceutically acceptable salt thereof, a hereinbefore defined, with a pharmaceutically acceptable diluent or carrier.
  • An example of a pharmaceutical composition of the invention is an injectable solution containing a compound of the invention, or a pharmaceutically acceptable salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about pH 5, and optionally a surfactant to aid dissolution.
  • Liquid solution comprising a compound of formula Ia or Ib, or a salt thereof, dissolved in water.
  • Solution mg/mL
    Active Compound 5.0% w/v
    Pure water To 100%
    • Medical Use
  • Surprisingly, it has been found that the compounds defined in the present invention, as a free base or a pharmaceutically acceptable salt thereof, are well suited for inhibiting glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK-3 in mammals, including man, in need of such prevention and/or treatment.
  • GSK-3 is highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that compounds of the invention are well suited for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system. In particular, the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.
  • Other conditions are selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication.
  • Further conditions are selected from the group consisting predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies and androgenetic alopecia.
  • One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.
  • The dose required for the therapeutic or preventive treatment of a particular disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • The present invention relates also to the use of a compound of formula Ia or Ib as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
  • In the context of the present specification, the term “therapy” also includes “prevention” unless there are specific indications to the contrary. The terms “therapeutic” and “therapeutically” should be construed accordingly.
  • The invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula Ia or Ib, as hereinbefore defined.
    • Non-Medical Use
  • In addition to their use in therapeutic medicine, the compounds of formula Ia or Ib as a free base or a pharmaceutically acceptable salt thereof, are also useful as pharmacological tools is in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.
    • Methods of Preparation
  • The present invention also relates to processes for preparing the compound of formula Ia or Ib. Throughout the following description of such processes it is understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are for example described in “Protective Groups in Organic Synthesis”, T. W. Greene, P. G. M Wutz, Wiley-Interscience, New York, 1999.
    • Preparation of Intermediates
  • The process, wherein halo is halogen, R3, R4, R5, R6, X1, n and m, unless otherwise specified, are as defined hereinbefore, comprises,
  • (i) halogenation of a compound of formula II,
  • Figure US20090149460A1-20090611-C00004
  • wherein R2 is halogen, to obtain a compound of formula III, wherein halo is halogen e.g. bromine, chlorine or iodine, may be performed by an aromatic electrophilic substitution using a suitable halogenation agent such as Br2, Cl2, I2, ICl, SO2Cl2 or another suitable halogenation agent such as N-bromosuccinimid in an appropriate solvent such as acetonitrile, acetic acid, HCl/ethanol or water, with or without a suitable base e.g. an alkali metal acetate such as sodium acetate, at a reaction temperature between −20° C. and room temperature.
    (ii) conversion of a compound of formula IV, wherein halo is a halogen, e.g. bromine or iodine, to obtain a compound of formula V, wherein X1 is a direct bond and R6 is as defined above,
  • Figure US20090149460A1-20090611-C00005
  • that may be carried out by reaction with a suitable tin reagent such as a trialkyltin-R6 reagent e.g. tributyltin-R6 in the presence of a suitable catalyst such as bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)palladium(0) or bis(triphenylphosphine)palladium(II) acetate in a suitable solvent such as tetrahydrofuran, acetonitrile, toluene or N,N-dimethylformamide and at a temperature range between 25° C. and reflux. The reaction may be aided by the presence of tetraethyl ammonium chloride.
    (iii) reduction of a compound of formula VI to obtain a compound of formula VII,
  • Figure US20090149460A1-20090611-C00006
  • that may be carried out in a suitable solvent such as toluene, tetrahydrofuran, diethyl ether or a mixture of tetrahydrofuran and an alcohol such as methanol or ethanol in the presence of a suitable reducing reagent such as lithium borohydride or sodium borohydride and at a reaction temperature between 0° C. and reflux.
    (iv) oxidation of a compound of formula VII to obtain a compound of formula VIII,
  • Figure US20090149460A1-20090611-C00007
  • that may be carried out in a suitable solvent such as chloroform, tetrahydrofuran or pyridine in the presence of a suitable oxidizing reagent such as chromium (VI) oxide or manganese (IV) oxide and at a reaction temperature between 0° C. and +100° C.
    (v) conversion of a compound of formula VIII to obtain a compound of formula IX,
  • Figure US20090149460A1-20090611-C00008
  • that may be carried out in a suitable solvent such as an alcohol e.g. methanol in the presence of a suitable reagent such as tosylmethyl isocyanide and a suitable base such as potassium carbonate or sodium carbonate and at a reaction temperature between 0° C. and reflux.
    (vi) conversion of a compound of formula X to obtain a compound of formula XI,
  • Figure US20090149460A1-20090611-C00009
  • that may be carried out in a suitable solvent such as carbon disulfide in the presence of suitable reagents such as aluminum trichloride and chloroacetyl chloride and at a reaction temperature between 0° C. and reflux.
    (vii) Conversion of a compound of formula XI to obtain a compound of formula XII,
  • Figure US20090149460A1-20090611-C00010
  • that may be carried out in a suitable solvent such as toluene, dioxane or tetrahydrofuran in the presence of a suitable reagent such as thioformamide and a suitable base such as a trialkylamine e.g triethylamine, or potassium carbonate and at a reaction temperature between +25° C. and reflux.
    (viii) conversion of a compound of formula XI to obtain a compound of formula XIII,
  • Figure US20090149460A1-20090611-C00011
  • that may be carried out in a suitable solvent such as acetic acid in the presence of a suitable reagent such as thioacetamide and at a reaction temperature between +25° C. and reflux.
    (ix) conversion of a compound of formula XIV, wherein halo is halogen e.g. fluorine, chlorine or bromine, to a compound of formula XV may be carried out by
  • Figure US20090149460A1-20090611-C00012
  • activation of the acid function in a compound of formula XIV, with
    a) a halogenation reagent such as thionyl chloride or oxalyl chloride in a suitable solvent such as methylene chloride, chloroform or toluene or using the reagent neat and the reaction may occur at a temperature between 0° C. and +80° C., followed by the reaction with the appropriate amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as an alkali metal, an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between −20° C. and +80° C., or
    b) a suitable coupling reagent such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-N,N,N,N′-tetramethyluronium hexafluorophosphate, 1,1′-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate and in a suitable solvent such as methylene chloride, N,N-dimethylformamide or tetrahydrofuran and the reaction may occur at a temperature between +20° C. and +130° C., followed by addition of the appropriate amine R4R5NH and at a reaction temperature between +20° C. and +130° C.
    (x) conversion of a compound of formula XVI, wherein halo is halogen e.g. fluorine, chlorine or bromine, to a compound of formula XV may be carried out by
  • Figure US20090149460A1-20090611-C00013
  • the reaction with the appropriate amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine, the reaction may occur at a temperature between −20° C. and +80° C.
    (xi) Conversion of a compound of formula XVII, wherein halo is halogen e.g. fluorine, chlorine or bromine, to a compound of formula XVIII may be carried out by
  • Figure US20090149460A1-20090611-C00014
  • activation of the sulfonic acid function in the compound of formula XVII with a suitable halogenating reagent such as thionyl chloride or phosphorus oxychloride in a suitable solvent such as methylene chloride, chloroform, acetonitrile or toluene, and sulfolane may be added as a co-solvent to facilitate the reaction. A catalytic amount of N,N-dimethylacetamide may speed up the reaction and the reaction may occur at a temperature between 0° C. and +120° C., followed by the reaction with the appropriate substituted amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between −20° C. and +80° C.
    (xii) conversion of a compound of formula XIX, wherein halo is halogen e.g. fluorine, chlorine or bromine and R3 is hydrogen or a halogen e.g. fluorine, chlorine or bromine, to a compound of formula XVIIIa may be carried out by
  • Figure US20090149460A1-20090611-C00015
  • the reaction with the appropriate amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between −20° C. and +80° C.
    (xiii) reaction of a compound of formula XX, wherein halo is halogen, to a compound of formula XXI may be carried out by
  • Figure US20090149460A1-20090611-C00016
  • the reaction with an appropriate amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, acetonitrile or N,N-dimethylformamide with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkylamine base such as triethylamine and the reaction may occur at a temperature between 0° C. and +120° C.
    (xiv) reaction of a compound of formula XXII, wherein halo is halogen e.g. fluorine chlorine, bromine, to a compound of formula XXIII may be carried out by
  • Figure US20090149460A1-20090611-C00017
  • the reaction with an appropriate reagent R4OH in a suitable solvent such as acetonitrile, methylene chloride, chloroform, toluene or N,N-dimethylformamide in the presence of a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide, potassium hydroxide or sodium hydride or an alkylamine base such as triethylamine and the reaction may occur at a temperature between 0° C. and +80° C.
    (xv) Conversion of a compound of formula XXIV, wherein halo is halogen e.g. fluorine, chlorine, bromine, to a compound of formula XXV may be carried out by
  • Figure US20090149460A1-20090611-C00018
  • reacting a compound of formula XXIV with an appropriate amine R4R5NH in a suitable solvent such as methylene chloride, chloroform, acetonitrile or N,N-dimethylformamide with or without a suitable base such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or, an alkylamine base such as triethylamine or, a macroporous polystyrene anion-exchange resin such as MP-Carbonate or, a cross linked polystyrene-co-divinylbenzene such as PS-diisopropylethylamine and the reaction may occur at a temperature between 0° C. and +120° C.
    (xvi) reacting a compound of formula XXVI, wherein R4 is C1-6alkyl and halo is a halogen, e.g. fluorine, chlorine or bromine, with a compound of formula C (wherein R2 and m are as defined above e.g. compounds of formula III, V, IX, XII or XIII) to form a compound of formula XXVII,
  • Figure US20090149460A1-20090611-C00019
  • may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • The reaction is advantageously effected in the presence of a base. A suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively, such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • Figure US20090149460A1-20090611-C00020
  • (xvii) reacting a compound of formula XXV, wherein halo is a halogen, e.g. fluorine, chlorine or bromine, with a compound of formula C (wherein R2 and m are as defined above e.g. compounds of formula III, V, IX, XII or XIII), to form a compound of formula XXVIII, may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • The reaction is advantageously effected in the presence of a base. A suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively, such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • Methods of Preparation of End products
  • Another object of the invention are processes a, b, c, d and e for the preparation of compounds of general formula Ia and Ib, wherein halo is halogen, P, R1, R2, R3R4, R5, m and n, unless otherwise specified, are defined as hereinbefore, and salts thereof.
  • These processes comprise;
    a) reacting a compound of formula B (XV, XVIII, XVIIIa, XXI, XXIII), wherein L1 is a leaving group such as halogen, e.g. fluorine, chlorine or bromine, with a compound of formula C (e.g. compounds of formula III, V, IX, XII, XIII); wherein R1, R2 and m are as defined as hereinbefore to form a compound of formula Ia;
  • Figure US20090149460A1-20090611-C00021
  • The reaction of process a may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide and the reaction may occur at a temperature between +10° C. and +150° C.
  • The reaction is advantageously effected in the presence of a base. A suitable base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively, such a base may be an alkali metal hydride such as sodium hydride, or an alkali metal or alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride or, a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between −30° C. to +50° C.
  • b) reacting a compound of formula XXV, wherein halo is halogen, e.g. fluorine, chlorine or bromine, with a compound of formula C (e.g. compounds of formula III, V, IX, XII, XIII); wherein R1, R2 and m are as defined as hereinbefore); to form a compound of formula Ia;
  • Figure US20090149460A1-20090611-C00022
  • The reaction of process b may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan, an aromatic hydrocarbon solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide, the reaction may occur at a temperature between +10° C. and +150° C.
  • The reaction is advantageously effected in the presence of a base. Such a base may be an organic amine base such as pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine, diazabicyclo[5.4.0]undec-7-ene, tetramethylguanidine or an alkali metal or an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively, such a base may be an alkali metal hydride such as sodium hydride, an alkali metal or an alkaline earth metal amide such as sodium amide, sodium bis(trimethylsilyl)amide, potassium amide or potassium bis(trimethylsilyl)amide.
  • The N-oxide may be removed by using a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate and the reaction may occur at a temperature between 0° C. and +100° C.
  • When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between −30° C. to +50° C.
  • c) reacting a compound of formula XXVII, wherein R4 is C1-6alkyl, with the appropriate amine HNR4R5, to form a compound of formula Ia;
  • Figure US20090149460A1-20090611-C00023
  • The reaction of process c may be carried out by:
    i) the reaction of the compound of formula XXVII with the appropriate amine R4R5NH in a suitable solvent such as benzene, methylene chloride, chloroform, toluene or acetonitrile in the presence of a suitable reagent such as trimethyl aluminum and at a reaction temperature between 0° C. and reflux or,
    ii) the reaction of the compound of formula XXVII with the appropriate amine R4R5NH neat or in a suitable solvent such as methylene chloride, chloroform, toluene or acetonitrile with or without a suitable base such as an alkali metal, an alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide or an alkyl aminebase such as triethylamine, the reaction may occur at a temperature between −20° C. and +150° C.
  • When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between −30° C. to +50° C.
  • d) reduction of the N-oxide in the compound of formula XXVIII to form a compound of formula Ia;
  • Figure US20090149460A1-20090611-C00024
  • The N-oxide may be reduced by using a suitable reagent such as phosphorus trichloride in a suitable solvent such as methylene chloride, chloroform, toluene or ethyl acetate and the reaction may occur at a temperature between 0° C. and +100° C.
  • When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between −30° C. to +50° C.
  • e) fluorinating a compound of formula Ia to form a compound of formula Ib;
  • Figure US20090149460A1-20090611-C00025
  • The reaction of process e may be carried out in an appropriate solvent such as an ether e.g. tetrahydrofuran or 1,4-dioxan or mixtures thereof in the presence of a suitable fluorinating reagent such as 1-fluoro-2,4,6-trimethylpyridinium triflate and a suitable base such as n-butyllithium or sodium bis(trimethylsilyl)amide and at a reaction temperature between −40° C. and +80° C.
  • When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, or a carboxylic acid such as fumaric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or methylene chloride or mixtures thereof, the reaction may occur between −30° C. to +50° C.
    • Intermediates
  • The present invention further relates to new intermediates and the use of these intermediates in the preparation of compounds of formula Ia and Ib as defined hereinbefore.
  • In one aspect of the invention the intermediate is a compound according to formula XXV
  • Figure US20090149460A1-20090611-C00026
  • wherein halo is halogen; R3 is selected from halogen, nitro, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR4R5, C0-6alkylcyano, C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5, C0-6alkylNR4R5 and a group X1R6, wherein X is a direct bond, O, CONR7R8, SO2NR9R10, SO2R11 or NR12R13; R7, R9 and R12 each independently are hydrogen or C1-3alkyl; R8, R10, R11 and R13 are C0-4alkyl; R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W; and R6 is linked to R8, R10, R11 and R13.
  • In one embodiment of this aspect there are provided compounds according to formula XXV wherein R3 is C0-6alkylNR4R5; and n is 1.
  • In another aspect there are provided compounds, said compounds being:
    • 1-[(6-Chloropyridin-3-yl)methyl]-4-methylpiperazine;
    • 2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide;
    • 2-Chloro-5-(pyrrolidin-1-ylmethyl)pyridine 1-oxide;
    • 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methyl-1,4-diazepane;
    • 2-Chloro-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridine 1-oxide;
    • 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N,N-dimethylpyrrolidin-3-amine;
    • 2-Chloro-5-[(4-methylpiperidin-1-yl)methyl]pyridine 1-oxide;
    • 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-phenylpiperazine;
    • 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine;
    • 3-[[(6-Chloro-1-oxidopyridin-3-yl)methyl](ethyl)amino]propanenitrile;
    • N-(4-Chlorobenzyl)-N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methylamine;
    • N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-(2-furylmethyl)-N-methylamine;
    • N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-methyl-N-phenylamine;
    • 5-(Azetidin-1-ylmethyl)-2-chloropyridine 1-oxide;
    • 2-Chloro-5-[(3-methylpiperidin-1-yl)methyl]pyridine 1-oxide;
    • N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-cyclohexyl-N-methylamine;
    • 2-Chloro-5-(piperidin-1-ylmethyl)pyridine 1-oxide;
      as a free base or a salt thereof.
  • In another aspect of the invention the intermediate is a compound according to formula B (XV, XVIII, XVIIIa XXI, XXIII)
  • Figure US20090149460A1-20090611-C00027
  • wherein P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one atom is selected from nitrogen and L1 is a leaving group such as a halogen e.g. fluorine, chlorine or bromine; wherein R3 is selected from halogen, nitro, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR4R5, C0-6alkylcyano, C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5, C0-6alkylNR4R5 and a group X1R6, wherein X1 is a direct bond, O, CONR7R8, SO2NR9R10, SO2R11 or NR12R13; R7, R9 and R12 each independently are hydrogen or C1-3alkyl; R8, R10, R11 and R13 are C0-4alkyl; R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W; and R6 is linked to R8, R10, R11 and R13.
  • In one embodiment of this aspect there are provided compounds according to formula B (XV, XVIII, XVIIIa XXI, XXIII) wherein P is a pyridine or pyrimidine ring and L1 is a leaving group such as a halogen e.g. chlorine; wherein R3 is selected from C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5 and C0-6alkylNR4R5; n is 1.
  • In another aspect there are provided compounds, said compounds being:
    • 2-Chloro-N-[2-(dimethylamino)ethyl]isonicotinamide;
    • 1-(2-Chloroisonicotinoyl)-4-methylpiperazine;
    • 6-Chloro-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide;
    • 4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;
    • 1-Benzyl-4-[(6-chloropyridine-3-yl)sulfonyl]piperazine;
    • 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(3-methylbutyl)piperazine;
    • 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-isopropylpiperazine;
    • 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-ethylpiperazine;
    • 1-[(5-Bromo-6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine;
    • 6-Chloro-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
    • 6-Chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide;
    • 6-Chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide;
    • 6-Chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide;
    • 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane;
    • 4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine;
      as a free base or a salt thereof.
  • In yet another aspect of the invention the intermediate is a compound according to formula C (III, V, IX, XII, XIII)
  • Figure US20090149460A1-20090611-C00028
  • wherein R1 is hydrogen; R2 is selected from halogen, nitro, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR4R5, C0-6alkylcyano, C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5, C0-6alkylNR4R5 and a group X1R6, wherein X1 is a direct bond, O, CONR7R8, SO2NR9R10, SO2R11 or NR12R13; R7, R9 and R12 each independently are hydrogen or C1-3alkyl; R8, R10, R11 and R13 are C0-4alkyl; R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W; and R6 is linked to R8, R10, R11 and R13.
  • In one embodiment of this aspect there are provided compounds according to formula C (III, V, IX, XII, XIII) wherein R1 is hydrogen; R2 is selected from halogen and a group X1R6, wherein X1 is a direct bond; R6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S; m is 1 or 2.
  • In another aspect there are provided compounds, said compounds being:
    • 5,6-Dibromo-1,3-dihydroindol-2-one;
    • 55-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one;
    • 5-Thien-2-yl-1,3-dihydro-2H-indol-2-one;
    • 5-(2-Furyl)-1,3-dihydro-2H-indol-2-one;
    • 5-(1,3-Oxazol-5-yl)-1,3-dihydro-2H-indol-2-one;
    • 5-(1,3-Thiazol-4-yl)-1,3-dihydro-2H-indol-2-one;
    • 5-(2-Methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one;
      as a free base or a salt thereof.
  • In yet another aspect of the invention the intermediate is a compound according to formula XXVII
  • Figure US20090149460A1-20090611-C00029
  • wherein R1 is hydrogen; R2 is selected from halogen, nitro, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR4R5, C0-6alkylcyano, C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5, C0-6alkylNR4R5 and a group X1R6, wherein X is a direct bond, O, CONR7R8, SO2NR9R10, SO2R11 or NR12R13; R7, R9 and R12 each independently are hydrogen or C1-3alkyl; R8, R10, R11 and R13 are C0-4alkyl; R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W; and R6 is linked to R8, R10, R11 and R13.
  • In one embodiment of this aspect there are provided compounds according to formula XXVII, wherein R1 is hydrogen; R2 is selected from nitro and cyano; m is 1.
  • In another aspect there are provided compounds, said compounds being:
    • Ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate;
    • Ethyl 6-(2-hydroxy-5-cyano-1H-indol-3-yl)nicotinate;
      as a free base or a salt thereof.
  • In yet another aspect of the invention the intermediate is a compound according to formula XXVIII
  • Figure US20090149460A1-20090611-C00030
  • wherein R1 is hydrogen; R2 is selected from halogen, nitro, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR4R5, C0-6alkylcyano, C0-6alkylCONR4R5, C0-6alkyl(SO2)NR4R5, C0-6alkylNR4R5 and a group X1R6, wherein X1 is a direct bond, O, CONR7R8, SO2NR9R10, SO2R11 or NR12R13; R7, R9 and R12 each independently are hydrogen or C1-3alkyl; R8, R10, R11 and R13 are C0-4alkyl; R6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S, which heterocyclic group may be saturated or unsaturated or said phenyl or 5-, 6- or 7-membered heterocyclic group may optionally be fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O and S and which phenyl or heterocyclic group may be substituted with one or two substituents selected from W; and R6 is linked to R8, R10, R11 and R13.
  • In one embodiment of this aspect there are provided compounds according to formula XXVIII, wherein R1 is hydrogen; R2 is a group X1R6, wherein X1 is a direct bond; R6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N, O and S; m is 1
  • In yet another aspect there are provided compounds, said compounds being:
    • 3-[5-(Morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol;
    • 3-[5-(Morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol;
    • 5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-1H-indol-2-ol;
      as a free base or a salt thereof.
  • In yet another aspect there are provided compounds, said compounds being:
    • 5-(Hydroxymethyl)-1,3-dihydro-2H-indol-2-one;
    • 2-Oxoindoline-5-carbaldehyde;
    • 5-(Chloroacetyl)-1,3-dihydro-2H-indol-2-one;
      as a free base or a salt thereof.
  • A further aspect of the invention relates to use of the compounds according to any one of formulas XXV; B (XV, XVIII, XVIIIa XXI, XXIII); C (III, V, IX, XII, XIII); XXVII; XXVIII; in the preparation of a compound of formula Ia or Ib.
    • WORKING EXAMPLES
  • The invention will now be illustrated in the following non-limiting Examples and unless stated otherwise:
  • (i) temperatures are given in degrees Celsius (° C.); operations were carried out at room temperature, i.e. at a temperature in the range of 18 to 25° C.;
    (ii) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
    (iii) when given, NMR data is in the form of delta values, given in parts per million (ppm) relative to the solvent or relative to tetramethylsilane (TMS) as an internal standard;
    (iv) chemical symbols have their usual meanings; SI units and symbols are used;
    (v) solvent ratios are given in volume:volume (v/v) terms; and
    (vi) mass spectra: where indicated, ionization was effected by chemical ionization (CI), electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP) unless otherwise indicated; values for m/z are given; generally, only ions which indicate the parent mass are reported.
    • Example 1 2-Chloro-N-[2-(dimethylamino)ethyl]isonicotinamide
  • To a solution of 2-chloroisonicotinic acid (0.50 g, 3.17 mmol) in N,N-dimethylformamide (20 mL) was added 1,1′-carbonyldiimidazole (0.565 g, 3.49 mmol). The solution was heated at 70° C. for 30 min. The reaction mixture was cooled to room temperature and N,N-dimethylethane-1,2-diamine (0.31 g, 3.49 mmol) was added. The solution was stirred at room temperature overnight. The solvent was evaporated in vacuo and the residue was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (90:10:1), as the eluent to afford 40 mg (5.7% yield) of the title compound as a colorless oil: 1H NMR (CDCl3, 400 MHz) δ 8.51 (d, J=5 Hz, 1H), 7.68 (s, 1H), 7.56 (dd, J=5, 1 Hz, 1H), 6.92-7.08 (br s, 1H), 3.58-3.48 (m, 2H), 2.59-2.52 (m, 2H), 2.28 (s, 6H); MS (TSP) m/z 228 (M++1).
    • Example 2 1-(2-Chloroisonicotinoyl)-4-methylpiperazine
  • The title compound was prepared as described for Example 1 using 2-chloroisonicotinic acid and 1-methylpiperazine. The crude product was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (100:10:1), as the eluent to give the title compound as a colorless oil. Yield: 68%: 1H NMR (CDCl3, 400 MHz) δ 8.51 (d, J=5 Hz, 1H), 7.57 (s, 1H), 7.43 (dd, J=5, 1 Hz, 1H), 3.66-3.58 (m, 2H), 3.28-3.21 (m, 2H), 2.41-2.34 (m, 2H), 2.30-2.24 (m, 2H), 2.20 (s, 3H); MS (TSP) m/z 240 (M++1).
    • Example 3 6-Chloro-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide
  • To a solution of N,N,′N-trimethylethylenediamine (1.0 g, 10 mmol) and triethylamine (2.0 g, 20 mmol) in methylene chloride (25 mL) was added 6-chloronicotinyl chloride (1.7 g, 10 mmol) in methylene chloride (50 mL) at room temperature. After 2 h at room temperature, the solvent was removed in vacuo and the residue was partitioned between a 2 M aqueous NaOH solution and methylene chloride. The combined extracts were dried (Na2SO4) and the solvent was removed in vacuo to afford 2.6 g of a crude product. The residue was purified on a silica gel column using acetonitrile/triethylamine, (90:10), as the eluent to afford 2.1 g (87% yield) of the title compound as an bright yellow oil: 1H NMR (DMSO-d6, 400 MHz) δ 8.62 (d, J=2 Hz, 1H), 8.06 (dd, J=8, 2 Hz, 1H), 7.76 (d, J=8 Hz, 1H), 3.70 (s, 1H), 3.41 (s, 1H), 3.12 (d, J=19 Hz, 3H), 2.64 (s, 1H), 2.51 (s, 1H), 2.37 (s, 3H), 2.13 (s, 3H); MS (TSP) m/z 242 (M++1).
    • Example 4 4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine
  • To a solution of N-(2-hydroxyethyl)morpholine (1.09 g, 8.27 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (364 mg, 9.10 mmol, 60% dispersion in oil) in portions. The mixture was stirred at room temperature for 1 h and at 45° C. for 1.5 h. The greenish solution was added dropwise over 5 min to a solution of 4,6-dichloropyrimidine (3.0 g, 20.1 mmol) in N,N-dimethylformamide (5 mL). The solvent was removed in vacuo, and the residue was partitioned between water and ethyl acetate. The organic layer was dried (Na2SO4) and the solvent was removed in vacuo. The crude product was purified on a silica gel column using ethyl acetate as the eluent affording 1.17 g (58% yield) of the title compound as a yellow oil: 1H NMR (CDCl3, 400 MHz) δ 8.57 (s, 1H), 6.80 (s, 1H), 4.53 (t, J=6 Hz, 2H), 3.72 (t, J=5 Hz, 4H), 2.77 (t, J=6 Hz, 2H), 2.55 (t, J=4 Hz, 4H); 13C NMR (CDCl3, 100 MHz) δ 170.0, 160.7, 158.1, 108.0, 66.9, 64.6, 57.1, 53.9; MS (ESP) m/z 244 (M++1).
    • Example 5 1-[(6-Chloropyridin-3-yl)methyl]-4-methylpiperazine
  • To a suspension of 2-chloro-5-(chloromethyl)pyridine (971 mg, 5.99 mmol) in acetonitrile (50 mL) was added a solution of N-methylpiperazine (1.20 g, 12.0 mmol) in acetonitrile (3 mL) followed by potassium carbonate (0.83 g, 5.99 mmol). The obtained yellow solution was heated is at reflux for 40 min. The mixture was allowed to cool for 10 min and the solvent was removed in vacuo. The residue was partitioned between water, NaCl (s), and ethyl acetate. The aqueous layer was extracted with another portion of ethyl acetate. The combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo affording 1.0 g (74% yield) of the title compound as a yellow oil: 1H NMR (CDCl3, 400 MHz) δ 8.31 (d, J=2 Hz, 1H), 7.65 (dd, J=8, 2 Hz, 1H), 7.29 (d, J=8 Hz, 1H), 3.49 (s, 2H), 2.46 (br s, 8H), 2.28 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 150.2, 150.1, 139.5, 132.8, 124.0, 59.2, 55.0, 53.0, 46.0; MS (ESP) m/z 226 (M++1).
    • Example 6 2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide
  • A mixture of 2-chloro-5-(chloromethyl)pyridine 1-oxide (1.16 g, 6.52 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333), morpholine (1.14 g, 13.0 mmol), and potassium carbonate (0.90 g, 6.52 mmol) in acetonitrile (30 mL) was stirred at room temperature for 72 h. The solvent was removed in vacuo and the residue was purified on a silica gel column using chloroform/ethanol, (9:1), as the eluent affording 1.21 g (81% yield) of the title compound as a colorless solid: mp 72-74° C.; 1H NMR (CDCl3, 400 MHz) δ 8.34 (s, 1H), 7.39 (d, J=8 Hz, 1H), 7.16 (dd, J=8.2 Hz, 1H), 3.65 (t, J=5 Hz, 4H), 3.40 (s, 2H), 2.40 (t, J=4 Hz, 4H); 13C NMR (CDCl3, 100 MHz) δ 140.4 (br), 135.9, 126.6, 126.6, 66.8, 59.2, 53.4; MS (ESP) m/z 229 (M++1).
    • Example 7 6-Chloro-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide
  • The title compound was prepared as described for Example 3 using 2-pyrrolidin-1-yl-ethylamine and 6-chloropyridine-3-sulfonyl chloride (described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750). Purification on a silica gel column using ethyl acetate/triethylamine, (9:1), as the eluent gave the title compound. Yield: 58%: 1H NMR (CDCl3, 400 MHz) δ 8.79 (d, J=2 Hz, 1H), 8.05 (dd, J=8, 3 Hz, 1H), 7.42 (d, J=9 Hz, 1H), 3.00 (app. t, J=6 Hz, 2H), 2.50 (app. t, J=6 Hz, 2H), 2.33 (m, 4H), 1.67 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 155.7, 148.8, 137.8, 136.1, 125.0, 54.1, 53.9, 41.6, 23.9; MS (TSP) m/z 290 (M++1).
    • Example 8 2-Chloro-5-(pyrrolidin-1-ylmethyl)pyridine 1-oxide
  • To a solution of 2-chloro-5-(chloromethyl)pyridine 1-oxide (477 mg, 2.68 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) in acetonitrile (10 mL) was added pyrrolidine (381 mg, 5.36 mmol), and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated, and the residue was dissolved in 2 M HCl(aq) and washed with ethyl acetate. The aqueous layer was alkalized to pH 8 with NaHCO3 (s), and the mixture was extracted four times with ethyl acetate. The combined organic layers were dried (Na2SO4), and the solvent was evaporated to give 0.43 g (75% yield) of the title compound as a red oil: 1H NMR (CDCl3, 400 MHz) δ 8.37 (d, J=1 Hz, 1H), 7.44 (d, J=8 Hz, 1H), 7.23 (dd, J=8, 2 Hz, 1H), 3.57 (s, 2H), 2.51 (m, 4H), 1.80 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 140.1, 139.9, 137.2, 126.4, 126.4, 56.4, 54.0, 23.5; MS (ES) m/z 213 (M++1).
    • Example 9 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methyl-1,4-diazepane
  • To a solution of 2-chloro-5-(chloromethyl)pyridine 1-oxide (940 mg, 5.28 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) in acetonitrile (30 mL) were added N-methylhomopiperazine (1.21 g, 10.6 mmol), and K2CO3 (730 mg, 5.28 mmol). The reaction mixture was stirred at room temperature for 3.5 days. The solvent was removed in vacuo, and the residue was partitioned between brine and ethyl acetate. The aqueous layer was extracted with another two portions of ethyl acetate and one portion of tetrahydrofuran. The combined organic layers were dried (Na2SO4), and evaporated to give 0.86 g (64% yield) of the title compound as an orange oil: 1H NMR (acetone-d6, 400 MHz) δ 8.30 (dd, J=2 Hz, 1H), 7.60 (d, J=8 Hz, 1H), 7.29 (dd, J=8, 2 Hz, 1H), 3.65 (s, 2H), 2.74-2.69 (m, 4H), 2.62-2.54 (m, 4H), 2.29 (s, 3H), 1.81-1.75 (m, 2H); MS (ES) m/z 256 (M++1).
  • The following Examples, 10-11, were prepared as described for Example 9:
    • Example 10 2-Chloro-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridine 1-oxide
  • Starting material: 4-(1-pyrrolidinyl)piperidine. Yield: 93%: 1H NMR (CDCl3, 400 MHz) δ 8.33 (d, J=1 Hz, 1H), 7.41 (d, J=8 Hz, 1H), 7.21 (dd, J=8, 2 Hz, 1H), 3.41 (s, 2H), 2.83-2.78 (m, 2H), 2.58-2.53 (m, 4H), 2.15-2.00 (m, 3H), 1.88-1.83 (m, 2H), 1.81-1.75 (m, 4H), 1.61-1.53 (m, 2H); MS (ES) m/z 296 (M++1).
    • Example 11 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N,N-dimethylpyrrolidin-3-amine
  • Starting material: 3-(dimethylamino)pyrrolidine. Yield: 67%: 1H NMR (aceton-d6, 400 MHz) δ 8.28 (d, J=1 Hz, 1H), 7.60 (d, J=8 Hz, 1H), 7.27 (dd, J=8, 2 Hz, 1H), 3.66-3.53 (m, 2H), 2.76-2.63 (m, 2H), 2.58-2.50 (m, 1H), 2.43-2.35 (m, 1H), 2.24-2.21 (m, 1H), 2.12 (s, 6H), 1.96-1.89 (m, 1H), 1.74-1.64 (m, 1H); MS (ES) m/z 256 (M++1).
    • Example 12 2-Chloro-5-[(4-methylpiperidin-1-yl)methyl]pyridine 1-oxide
  • To a solution of 2-chloro-5-(chloromethyl)pyridine 1-oxide (222 mg, 1.25 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) in tetrahydrofuran (2 mL) were added a solution of 4-methylpiperidine (247 mg, 2.49 mmol) in tetrahydrofuran (1.5 mL), a catalytic amount of potassium iodide, and MP-Carbonate (2.55 mmol/g, 1.47 g, 3.74 mmol). The mixture was gently stirred at room temperature for one week. The mixture was filtered (20 μm polyethylene filter), and the beads were washed with several portions of methylene chloride. The filtrate was washed with NaHCO3 (aq. sat.), dried (Na2SO4), and the solvent was evaporated to give a crude product which was purified by column chromatography using chloroform/ethanol, (95:5), as the eluent to give 168 mg (56% yield) of the title compound as a yellow oil: 1H NMR (CDCl3, 400 MHz) δ 8.37 (d, J=1 Hz, 1H), 7.41 (d, J=8 Hz, 1H), 7.20 (dd, J=8, 2 Hz, 1H), 3.41 (s, 2H), 2.80-2.75 (m, 2H), 2.00 (dt, J=12, 2 Hz, 2H), 1.63-1.58 (m, 2H), 1.45-1.30 (m, 1H), 1.22 (m, 2H), 0.92 (d, J=6 Hz, 3H); MS (ES) m/z 241 (M++1).
    • Example 13 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-phenylpiperazine
  • PS-Diisopropylethylamine (3.54 mmol/g, 0.4 g, 1.40 mmol) was washed with tetrahydrofuran and 2-chloro-5-(chloromethyl)pyridine 1-oxide (100 mg, 0.56 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) was added followed by tetrahydrofuran (1 mL). A solution of 1-phenylpiperazine (182 mg, 1.12 mmol) in tetrahydrofuran (1 mL) and a catalytic amount of potassium iodide were added, and the mixture was gently stirred (100 r/min) at room temperature for one week. PS-Isocyanate (1.76 mmol/g, 0.80 g, 1.40 mmol) was washed with tetrahydrofuran and added to the mixture followed by additional tetrahydrofuran (1 mL). The suspension was gently stirred (100 r/min) at room temperature for 19 h. The suspension was filtered (20 μm polyethylene filter), and the resins were washed with methylene chloride, tetrahydrofuran, and ethanol. Volatiles were removed in vacuo, and the residue was suspended in a 1:1-mixture of tetrahydrofuran and ethanol (8 mL) followed by the addition of N-ethyl-N,N-diisopropylamine (50 μL, 0.28 mmol). The mixture was added to PS-Thiophenol (1.35 mmol/g, 0.21 g, 0.28 mmol), and MP-Carbonate (3.20 mmol/g, 90 mg, 0.28 mmol), both pre-swelled in tetrahydrofuran. The mixture was stirred (100 r/min) at room temperature overnight followed by filtration. The resins were washed with methylene chloride, tetrahydrofuran, and ethanol, and the filtrate was concentrated in vacuo to give 141 mg (83% yield) of the title compound: 1H NMR (CDCl3, 400 MHz) δ 8.42 (s, 1H), 7.45 (d, J=8 Hz, 1H), 7.30-7.26 (m, 2H), 7.25-7.21 (m, 1 H), 6.95-6.90 (m, 2H), 6.89-6.85 (m, 1H), 3.51 (s, 2H), 3.22-3.18 (m, 4H), 2.65-2.60 (m, 4H); MS (ES) m/z 304 (M++1).
  • The following Examples, 14-19, were prepared as described for Example 13:
    • Example 14 1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine
  • Starting material: 1-[2-nitro-4-(trifluoromethyl)phenyl]piperazine. Yield: 100%: 1H NMR (CDCl3, 400 MHz) δ 8.43 (d, J=1 Hz, 1H), 8.06 (d, J=2 Hz, 1H), 7.68 (dd, J=9, 2 Hz, 1H), 7.45 (d, J=8 Hz, 1H), 7.19 (dd, J=8, 2 Hz, 1H), 7.16 (d, J=9 Hz, 1H), 3.54 (s, 2H), 3.18 (t, J=5 Hz, 4H), 2.64 (t, J=5 Hz, 4H); MS (ES) m/z 417 (M++1).
    • Example 15 3-[[(6-Chloro-1-oxidopyridin-3-yl)methyl](ethyl)amino]propanenitrile
  • Starting material: 3-(ethylamino)propionitrile. Yield: 82%: 1H NMR (CDCl3, 400 MHz) δ 8.35 (d, J=1 Hz, 1H), 7.46 (d, J=8 Hz, 1H), 7.32 (dd, J=9, 1 Hz, 1H), 3.60 (s, 2H), 2.82 (t, J=7 Hz, 2H), 2.60 (q, J=7 Hz, 2H), 2.47 (t, J=7 Hz, 2H), 1.07 (t, J=7 Hz, 3H); MS (ES) m/z 240 (M++1).
    • Example 16 N-(4-Chlorobenzyl)-N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methylamine
  • Starting material: p-chloro-N-methylbenzylamine. Yield: 100%: 1H NMR (CDCl3/DMSO-d6, 7:1, 400 MHz) δ 8.39 (s, 1H), 7.46 (dd, J=8, 1 Hz, 1H), 7.34-7.26 (m, 4H), 7.24-7.20 (m, 1H), 3.54 (d, J=2 Hz, 2H), 3.45 (s, 2H), 2.20 (d, J=2 Hz, 3H); MS (ES) m/z 297 (M++1).
    • Example 17 N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-(2-furylmethyl)-N-methylamine
  • Starting material: N-methylfurfurylamine. Yield: 71%: 1H NMR (CDCl3, 400 MHz) δ 8.37 (d, J=1 Hz, 1H), 7.43 (d, J=8 Hz, 1H), 7.39 (dd, J=2, 1 Hz, 1H), 7.22 (dd, J=8, 2 Hz, 1H), 6.34 (dd, J=3, 2 Hz, 1H), 6.22-6.20 (m, 1H), 3.61 (s, 2H), 3.46 (s, 2H), 2.26 (s, 3H); MS (ES) m/z 253 (M++1).
    • Example 18 N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-methyl-N-phenylamine
  • Starting material: N-methylaniline. Yield: 100%: 1H NMR (CDCl3, 400 MHz) δ 8.26 (d, J=1 Hz, 1H), 7.42 (d, J=8 Hz, 1H), 7.26-7.20 (m, 2H), 7.10-7.06 (m, 1H), 6.81-6.75 (m, 1H), 6.71-6.67 (m, 2H), 4.45 (s, 2H), 3.02 (s, 3H); MS (ES) m/z 249 (M++1).
    • Example 19 5-(Azetidin-1-ylmethyl)-2-chloropyridine 1-oxide
  • Starting material: azetidine. Yield: 100%: MS (ES) m/z 199 (M++1).
    • Example 20 2-Chloro-5-[(3-methylpiperidin-1-yl)methyl]pyridine 1-oxide
  • PS-Diisopropylethylamine (3.54 mmol/g, 0.4 g, 1.40 mmol) was washed with tetrahydrofuran and 2-chloro-5-(chloromethyl)pyridine 1-oxide (100 mg, 0.56 mmol; described in: Tilley, J. W. et al, J. Heterocyclic Chem. 1979, 16, 333) was added followed by tetrahydrofuran (1 mL). A solution of 3-methylpiperidine in tetrahydrofuran (1.5 mL) and a catalytic amount of potassium iodide were added, and the mixture was gently stirred (80 r/min) at room temperature for 5 days. PS-Isocyanate (1.10 mmol/g, 1.27 g, 1.40 mmol) was washed with tetrahydrofuran and added to the mixture followed by additional tetrahydrofuran (2 mL). The suspension was gently stirred (80 r/min) at room temperature overnight. N-Ethyl-N,N-diisopropylamine (50 μL, 0.28 mmol) and MP-Carbonate (2.55 mmol/g, 0.66 g, 1.68 mmol) were added, and the contents were mixed and gently stirred for 24 h. The mixture was filtered (20 μm polyethylene filter), and the resins were washed with methylene chloride. Volatiles were removed in vacuo to give 138 mg (99% yield) of the title compound: MS (ES) m/z 241 (M++1).
  • The following Examples, 21-22, were prepared as described for Example 20:
    • Example 21 N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-cyclohexyl-N-methylamine
  • Starting material: N-methylcyclohexylamine. Yield: 96%: MS (ES) m/z 255 (M++1).
    • Example 22 2-Chloro-5-(piperidin-1-ylmethyl)pyridine 1-oxide
  • Starting material: piperidine: MS (ES) m/z 227 (M++1)
    • Example 23 6-Dibromo-1,3-dihydroindol-2-one
  • 6-Bromooxindole (0.168 g, 0.8 mmol) was dissolved in acetic acid (4 mL) and stirred for 5 min at room temperature. N-Bromosuccinimide (0.14 g, 0.8 mmol) was added and the yellow reaction mixture was stirred for 3 h at ambient temperature. The mixture was poured onto ice and the resulting precipitate was collected by filtration and dried in vacuo to give 0.192 g (83% yield) of the title compound as a white solid: 1H NMR (DMSO-d6, 400 MHz) δ 10.61 (s, 1H), 7.60 (s, 1H), 7.14 (s, 1H), 3.52 (s, 2H).
    • Example 24 1-Benzyl-4-[(6-chloropyridine-3-yl)sulfonyl]piperazine
  • To a solution of benzylpiperazine (0.45 mL, 2.59 mmol) in methylene chloride (15 mL), cooled on an ice-bath, was 6-chloropyridine-3-sulfonyl chloride (0.50 g, 2.36 mmol; described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750) dissolved in methylene chloride (10 mL) added slowly. The reaction was stirred for 30 min and the formed white precipitation was filtered and washed with methylene chloride and water affording, after drying, 0.68 g (82% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 8.70 (d, J=3 Hz, 1H), 8.14 (dd, J=8, 3 Hz, 1H), 7.76 (d, J=8 Hz, 1H), 7.50-7.43 (m, 2H), 7.38-7.30 (m, 3H), 4.23 (br s, 2H), 3.79-3.63 (m, 2H), 3.45-3.18 (m, 2H), 3.11-2.96 (m, 2H), 2.96-2.81 (m, 2H); MS (ES) m/z 352 (M++1).
    • Example 25 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(3-methylbutyl)piperazine
  • To a solution of 1-(3-methylbutyl)piperazine (0.41 g, 2.60 mmol; described in: Yamane, T. et al. Chem. Pharm. Bull. 1993, 41, 148-155) in methylene chloride (15 mL) cooled on an ice-bath was 6-chloropyridine-3-sulfonyl chloride (0.50 g, 2.36 mmol; described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750) dissolved in methylene chloride (10 mL) added slowly. The reaction was stirred for 30 min and a 5% HCl(aq) solution (30 mL) was added and the phases were separated. The aqueous layer was alkalyzed with a saturated aqueous NaHCO3 solution until pH 9 and the mixture was extracted with methylene chloride. The organic layers were combined, dried (Na2SO4) and the solvent was removed in vacuo affording 650 mg (83% yield) of the title compound as a white solid: 1H NMR (CDCl3, 400 MHz) δ 8.75 (d, J=2 Hz, 1H), 7.97 (dd, J=8, 2 Hz, 1H), 7.51 (d, J=8 Hz, 1H), 3.33-3.05 (m, 4H), 2.86-2.29 (m, 6H), 1.66-1.50 (m, 1H), 1.5-1.28 (m, 2H), 0.88 (d, J=7 Hz, 6H); MS (ES) m/z 332 (M++1).
    • Example 26 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-isopropylpiperazine
  • The title compound was prepared as described for Example 25 using N-isopropylpiperazine and 6-chloropyridine-3-sulfonyl chloride (described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750). Yield: 89%: 1H NMR (CDCl3, 400 MHz) δ 8.73 (d, J=3 Hz, 1H), 7.96 (dd, J=8, 3 Hz, 1H), 7.48 (d, J=8 Hz, 1H), 3.12-3.01 (m, 4H), 2.76-2.63 (m, 1H), 2.63-2.54 (m, 4H), 0.99 (d, J=7 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 156.1, 149.3, 138.2, 131.7, 125.0, 54.8, 48.0, 46.7, 18.7; MS (ES) m/z 304 (M++1).
    • Example 27 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-ethylpiperazine
  • The title compound was prepared as described for Example 25 using N-ethylpiperazine and 6-chloropyridine-3-sulfonyl chloride (described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750). Yield: 83%: 1H NMR (CDCl3, 400 MHz) δ 8.75 (d, J=3 Hz, 1H), 7.97 (dd, J=8, 3 Hz, 1H), 7.50 (d, J=8 Hz, 1H), 3.16-3.06 (m, 4H), 2.60-2.46 (m, 4H), 2.42 (q, J=7 Hz, 2H), 1.04 (t, J=7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.8, 148.9, 137.8, 131.3, 124.7, 51.9, 51.6, 46.0, 11.9; MS (ES) m/z 290 (M++1).
    • Example 28 1-[(5-Bromo-6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine
  • The title compound was prepared as described for Example 3 using 1-methylpiperazine and 5-bromo-6-chloropyridine-3-sulfonyl chloride. Yield: 91%: 1H NMR (CDCl3, 400 MHz) δ 8.59 (d, J=2 Hz, 1H), 7.67 (d, J=2 Hz, 1H), 3.08-3.01 (m, 4H), 2.43 (t, J=5 Hz, 4H), 2.22 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.5, 146.8, 141.2, 132.7, 121.4, 54.2, 46.3, 46.1.
    • Example 29 6-Chloro-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide
  • To a solution of 6-chloropyridine-3-sulfonylchloride (636 mg, 3 mmol; described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750) in methylene chloride (10 mL) was added methyl-(2-pyrrolidin-1-ylethyl)amine (384 mg, 3 mmol; described in: J. Amer. Chem. Soc. 1955, 77, 3632-3634) dissolved in methylene chloride (10 mL) dropwise. The reaction mixture was stirred over night at room temperature followed by the extraction with aqueous HCl (3%). The acidic water layer was alkalized with an aqueous saturated solution of NaHCO3 and extracted with methylene chloride. The organic phase was dried (Na2SO4) and evaporated in vacuo to give 0.75 gram (80% yield) of the title compound: MS (ES) m/z 304 (M++1).
    • Example 30 6-Chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide
  • The title compound was prepared as described for Example 29 using 6-chloropyridine-3-sulfonylchloride and N,N-dimethylethane-1,2-diamine. Yield: 72%: MS (ES) m/z 264 (M++1).
    • Example 31 6-Chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide
  • To a solution of N′-ethyl-N,N-dimethylethane-1,2-diamine (0.62 mL, 4.4 mmol) in methylene chloride (10 mL) was added 6-chloropyridine-3-sulfonylchloride (0.85 g, 4 mmol; described in: Naegeli, C. et al. Helv. Chim. Actal. 1938, 21, 1746-1750) dissolved in methylene chloride (10 mL) dropwise. The reaction mixture was stirred for 30 min at room temperature followed by the extraction with aqueous HCl (5%). The acidic water layer was alkalized with an aqueous saturated solution of NaHCO3 and extracted with methylene chloride. The organic phase was dried (Na2SO4) and evaporated in vacuo to give 0.7 gram (60% yield) of the title compound: MS (ES) m/z 292 (M++1).
    • Example 32 6-Chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide
  • The title compound was prepared as described for Example 31 using (1-ethylpyrrolidin-2-yl)methylamine. Yield: 58%: MS (ES) m/z 304 (M++1).
    • Example 33 1-[(6-Chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane
  • The title compound was prepared as described for Example 31 using 1-methylhomopiperazine. Yield: 60%: MS (ES) m/z 290 (M++1).
    • Example 34 4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine
  • The title compound was prepared as described for Example 31 using morpholine. The crude product was purified on a silica gel column using heptane/ethyl acetate, (1:1), as the eluent: Yield: 60%: MS (ES) m/z 263 (M++1).
    • Example 35 Ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate
  • To a cooled solution of 5-nitrooxindol (5.27 g, 29.6 mmol) in N,N-dimethylamide (50 mL) was added sodium hydride (1.4 g, 35 mmol) during 5 min at 0° C. After 10 min at 0° C., 6-chloronicotinic acid ethyl ester (5.0 g, 26.9 mmol) was added dropwise and the reaction was heated to 135° C. for 45 min. The mixture was diluted with water (200 mL) and saturated NH4Cl(aq) (100 mL). The formed precipitate was filtrated and washed with water, methanol, ethyl acetate and diethyl ether. The residual green yellow solid was dried to give 4.1 g (47% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 14.57 (s, 1H), 11.24 (s, 1H), 8.73 (s, 1H), 8.26 (s, 1H), 8.10 (d, J=9 Hz, 1H), 7.92 (d, J=8 Hz, 1H), 7.67 (d, J=9 Hz, 1H), 7.03 (d, J=9 Hz, 1H), 4.31 (q, J=7 Hz, 2H), 1.32 (t, J=7 Hz, 3H).
    • Example 36 Ethyl 6-(2-hydroxy-5-cyano-1H-indol-3-yl)nicotinate
  • To a solution of 5-cyanooxindole (360 mg, 2.27 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (106 mg, 4.41 mmol). The greenish reaction mixture was stirred for 50 min whereafter 6-chloronicotinic acid ethyl ester (350 mg, 1.89 mmol) dissolved in N,N-dimethylformamide (5 mL) was added. The reaction mixture was heated at 110° C. for 30 min and water (50 mL) and saturated NH4Cl(aq) (20 mL) was added, followed by extraction with ethyl acetate. The phases were separated and the organic phase contained the title compound as a precipitation that was filtered off. The solvent was concentrated in vacuo and additional product precipitated that was filtered to give 200 mg (34% yield) of the title compound in total: 1H NMR (DMSO-d6, 300 MHz) δ 14.50 (br s, 1H), 11.00 (s, 1H), 8.73 (s, 1H), 7.95 (s, 2H), 7.80 (s, 1H), 7.48 (s, 1H), 6.95 (d, J=7 Hz, 1H), 4.50-4.15 (m, 2H), 1.32 (t, J=7 Hz, 3H).
    • Example 37 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
  • A mixture of 5-bromooxindole (0.95 g, 4.48 mmol), 3-(tri-n-butylstannyl)pyridine (1.65 g, 4.48 mmol), tetraethyl ammonium chloride (2.23 g, 13.4 mmol) and bis(triphenylphospine palladium (II) chloride (0.16 g, 0.22 mmol) in acetonitrile (20 mL) was heated at reflux over night. After cooling to ambient temperature the mixture was diluted with chloroform (100 mL) and a potassium fluoride solution (10%, 250 mL) was added. The mixture was filtered through Celite and the layers were separated. The organic layer was dried (Na2SO4) and the solvent was removed in vacuo. The residue was purified on a silica gel column using chloroform/ethanol, (50:1), as the eluent affording 165 mg (18% yield) of the title compound as a white solid: 1H NMR (DMSO-d6, 400 MHz) δ 9.64 (br s, 1H), 7.97 (d, J=2 Hz, 1H), 7.66 (dd, J=5, 1 Hz, 1H), 7.21-7.10 (m, 1H), 6.73 (s, 1H), 6.73-6.65 (m, 1H), 6.65-6.54 (m, 1H), 6.08 (d, J=8 Hz, 1H), 2.69 (s, 2H); MS (ES) m/z 211 (M++1).
    • Example 38 5-Thien-2-yl-1,3-dihydro-2H-indol-2-one
  • The title compound was prepared as described for Example 37 using 5-bromooxindole and tri-n-butyl(2-thienyl)tin: MS (ES) m/z 216 (M++1).
    • Example 39 5-(2-Furyl)-1,3-dihydro-2H-indol-2-one
  • The title compound was prepared as described for Example 37 using 5-bromooxindole and tri-n-butyl(2-furyl)tin: MS (ES) m/z 200 (M++1).
    • Example 40 5-(Hydroxymethyl)-1,3-dihydro-2H-indol-2-one
  • To an ice-cooled mixture of methyl 2-oxoindoline-5-carboxylate (0.5 gram, 2.6 mmol) in a tetrahydrofuran/ethanol mixture (15:0.3 mL) was added lithium borohydride (115 mg, 5.2 mmol) in one portion. After 30 min, another portion of lithium borohydride (100 mg, 4.5 mmol) was added and the reaction solution was stirred for 4 h at room temperature. A third portion of lithium borohydride (200 mg, 9.2 mmol) and ethanol (0.3 mL) were added and the reaction solution was stirred for 14 h at room temperature. The reaction was quenched with water (10 mL) and an aqueous saturated ammonium chloride solution (30 mL) and extracted with ethyl acetate. The combined organic phases were dried (Na2SO4) and evaporated in vacuo. The crude product was purified on a silica gel column using methylene chloride/methanol, (10:1) as the eluent to give 140 mg (33% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 10.3 (br s, 1H), 7.14 (s, 1H), 7.09 (d, J=8 Hz, 1H), 6.74 (d, J=8 Hz, 1H), 5.03 (t, J=6 Hz, 1H), 4.41 (7, J=6 Hz, 2H), 3.44 (s, 2H).
    • Example 41 2-Oxoindoline-5-carbaldehyde
  • Chromium (VI) oxide (240 mg, 2.4 mmol) was added to ice-cooled pyridine (3 mL). To the formed yellow suspension was added additional pyridine (2 mL) and 5-(hydroxymethyl)-1,3-dihydro-2H-indol-2-one (130 mg, 0.8 mmol) dissolved in pyridine (3 mL). The reaction was quenched after 15 min by the addition of water (50 mL) and extracted with ethyl acetate. The organic phases were dried (Na2SO4) and evaporated in vacuo. The crude product was purified on a silica gel column using methylene chloride/methanol, (10:1), as the eluent to give 60 mg (46% yield) of the title compound.
    • Example 42 5-(1,3-Oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • A mixture of 2-oxoindoline-5-carbaldehyde (60 mg, 0.38 mmol), tosylmethyl isocyanide (145 mg, 0.75 mmol) and potassium carbonate (103 mg, 0.75 mmol) in methanol (20 mL) was heated at reflux for 2 h. The mixture was concentrated in vacuo and diluted with an aqueous saturated solution of sodium hydrogencarbonate and extracted with methylene chloride. The combined organic layers were dried (Na2SO4) and evaporated in vacuo. The crude product was purified on a silica gel column using heptane/ethyl acetate, (1:4), as the eluent to give 40 mg (53% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 10.54 (br s, 1H), 8.36 (br s, 1H), 7.64-7.44 (m, 3H), 6.89 (d, J=8 Hz, 1H), 3.54 (br s, 2H).
    • Example 43 5-(Chloroacetyl)-1,3-dihydro-2H-indol-2-one
  • To a mixture of aluminum trichloride (17 gram, 128 mmol) and chloroacethyl chloride (3 gram, 2.65 mmol) in carbon disulfide (40 mL) was oxindole (2.73 gram, 20.5 mmol) added and the mixture was stirred at reflux for 3.5 h. The mixture was cooled to room temperature and carefully quenched with cooled water (50 mL). The quenched reaction mixture was stirred for 2 h and the formed precipitate was filtered and washed two times with water. The solid was dried to give 2.3 gram (53% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 10.82 (br s, 1H), 7.87 (d, J=8 Hz, 1H), 7.82 (s, 1H), 6.92 (d, J=8 Hz, 1H), 5.08 (s, 2H), 3.57 (s, 2H).
    • Example 44 5-(1,3-Thiazol-4-yl)-1,3-dihydro-2H-indol-2-one
  • A suspension of 5-(chloroacetyl)-1,3-dihydro-2H-indol-2-one (630 mg, 3 mmol), thioformamide (30 mL, 30 mmol; described in: J. Med. Chem. 1995, 858-868) and triethylamine (0.42 mL, 3 mmol) in dioxane was heated at 110° C. for 3 h. Additional thioformamide (10 mL, 10 mmol) was added and the reaction was stirred at 110° C. for 2 h.
  • This batch was combined with an new batch starting from 230 mg of 5-(chloroacetyl)-1,3-dihydro-2H-indol-2-one and the combined reaction mixtures was concentrated to approximately 10 mL and an aqueous saturated sodium hydrogencarbonate solution (50 mL) was added and the solution was extracted with ethyl acetate. The combined organic layers were dried (Na2SO4) and evaporated in vacuo. The crude product was purified on a silica gel column using heptane/ethyl acetate, (1:2), as the eluent to give 400 mg (35% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 10.47 (s, 1H), 9.15 (s, 1H), 7.97 (s, 1H), 7.83 (br s, 2H), 6.87 (d, J=8 Hz, 1H), 3.54 (s, 2H); MS (ES) m/z 217 (M++1).
    • Example 45 5-(2-Methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one
  • A suspension of 5-(chloroacetyl)-1,3-dihydro-2H-indol-2-one (1.5 g, 7.15 mmol) and thioacetamide (540 mg, 7.15 mmol) in acetic acid (18 mL) was heated at 80° C. for 3 h. The mixture was cooled to room temperature and the formed precipitate was filtered and washed with ethyl acetate two times and diethyl ether two times and the solid was dried under vacuo to give 1.5 gram (91% yield) of the title compound: 1H NMR (DMSO-d6, 300 MHz) δ 10.49 (s, 1H), 7.90-7.70 (m, 3H), 6.85-6.75 (m, 1H), 3.55 (s, 2H), 2.70 (s, 3H).
    • Example 46 3-[5-(Morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol
  • To a suspension of sodium hydride (0.05 g, 1.2 mmol, 60% dispersion in oil, pre-washed with hexane) in N,N-dimethylformamide (3 mL) was added a solution of 5-pyridin-3-yl-1,3-dihydro-2H-indol-2-one (0.19 g, 0.90 mmol) in N,N-dimethylformamide (4 mL). The mixture was stirred for 20 min under nitrogen atmosphere. 2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide (0.14 g, 0.60 mmol), dissolved in N,N-dimethylformamide (3 mL) was added dropwise and the mixture was stirred at room temperature for 2 h and then heated at 130° C. for 1.5 h. The solvent was evaporated in vacuo and the residue was partitioned between 2 M HCl and ethyl acetate and the phases were separated. The aqueous layer was alkalized by addition of NaHCO3 (s) and extracted with ethyl acetate. The organic layer was dried (Na2SO4) and the solvent was removed in vacuo affording 200 mg of the title compound as a yellow solid: MS (ES) m/z 403 (M++1).
    • Example 47 3-[5-(Morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol
  • The title compound was prepared as described for Example 46 using 5-thien-2-yl-1,3-dihydro-2H-indol-2-one: MS (ES) m/z 408 (M++1).
    • Example 48 5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-1H-indol-2-ol
  • The title compound was prepared as described for Example 46 using 5-(2-furyl)-1,3-dihydro-2H-indol-2-one: MS (ES) m/z 392 (M++1).
    • Example 49 2-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]isonicotinamide
  • To a suspension of sodium hydride (0.15 g, 3.70 mmol, 60% dispersion in oil, pre-washed with hexane) in N,N-dimethylformamide (3 mL) was added a solution of 5-cyanooxindole (0.29 g, 1.84 mmol) in N,N-dimethylformamide (4 mL). The mixture was stirred for 30 min under a nitrogen atmosphere. 2-Chloro-N-[2-(dimethylamino)ethyl]isonicotinamide (0.21 g, 0.92 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise and the mixture was stirred at room temperature for 30 min and then heated at 150° C. for 45 min. The solvent was evaporated in vacuo and the residue was partitioned between ethyl acetate and water. A 2 M aqueous HCl solution was added until pH 2 and the mixture was extracted with ethyl acetate. To the aqueous layer, a 45% aqueous NaOH solution was added until pH 11 and the suspension was extracted with ethyl acetate. The aqueous layer was concentrated in vacuo and the crude product was purified by preparative HPLC (column: Xterra, 19×300 mm, eluent: 0.05 M NH4OAc buffert/acetonitrile, 9:1 to 3:7) to give 15 mg (5% yield) of the title compound as a red solid: 1H NMR (DMSO-d6, 400 MHz) δ 14.88 (br s, 1H), 11.03 (br s, 1H), 9.10 (br s, 1H), 8.28 (d, J=6 Hz, 1H), 8.04-7.96 (m, 1H), 7.95-7.83 (m, 1H), 7.42-7.34 (m, 1H), 7.13-7.02 (m, 2H), 3.62-3.50 (m, 2H), 2.86-2.69 (m, 2H), 2.58-2.29 (m, 6H); MS (TSP) m/z 350 (M++1).
    • Example 50 2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • The reaction was performed as described in Example 49 using 5-cyanooxindole and 1-(2-chloroisonicotinoyl)-4-methylpiperazine. The crude product was purified on a silica gel column using chloroform/ethanol/conc. NH3(aq), (100:10:1), as the eluent. The base (20 mg) was dissolved in chloroform and a solution of HCl in diethyl ether was added until acidic pH. The formed precipitation was filtered and washed with diethyl ether. Drying in vacuo afforded 10 mg the title compound as a red solid. Yield: 2%: 1H NMR (D2O, 400 MHz) δ 7.82-7.77 (m, 1H), 7.18-7.11 (m, 1H), 7.09-7.05 (m, 1H), 7.04-6.98 (m, 1H), 6.78-6.71 (m, 1H), 6.67-6.61 (m, 1H), 4.05-3.94 (m, 1H), 3.93-3.82 (m, 1H), 3.67-3.48 (m, 2H), 3.48-3.37 (m, 1H), 3.35-3.04 (m, 3H), 2.92-2.80 (m, 3H); MS (TSP) m/s 362 (M++1).
    • Example 51 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile
  • A mixture of 5-cyanooxindole (213 mg, 1.35 mmol) and sodium hydride (72 mg, 1.80 mmol, 60% dispersion in oil) in N,N-dimethylformamide (4 mL) was stirred at room temperature for 10 min. A solution of 1-[(6-chloropyridin-3-yl)carbonyl]-4-methylpiperazine (216 mg, 0.901 mmol; described in: Thunus, L. Ann. Pharm. Fr. 1977, 35(5-6), 197-203) in N,N-dimethylformamide (2 mL) was added dropwise. The reaction was stirred at room temperature for 3 h, then at 50° C. for 2.5 h. The solvent was removed in vacuo, and the residue was partitioned between chloroform and water. The phases were separated and the pH of the water phases was adjusted to 8 with a 2 M aqueous solution of HCl. The aqueous layer was extracted with ethyl acetate and the organic layers were dried (Na2SO4), combined, and the solvent was removed in vacuo affording an orange semi-solid. The material was purified on a silica gel column using chloroform/methanol, (8:2), as the eluent affording 24 mg (7% yield) of the title compound as a yellow solid: mp decomposes >295° C.; 1H NMR (CDCl3, 400 MHz) δ 7.95 (s, 1H), 7.91 (s, 1H), 7.74 (dd, J=9, 2 Hz, 1H), 7.69 (s, 1H), 7.48 (d, J=9 Hz, 1H), 7.36 (dd, J=8, 1 Hz, 1H), 7.06 (d, J=8 Hz, 1H), 3.69 (br s, 4H); 2.48 (br s, 4H), 2.36 (s, 3H); MS (TSP) m/z 362 (M++1).
    • Example 52 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride
  • To a suspension of 5-cyanooxindole (720 mg, 4.55 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (248 mg, 6.2 mmol, 60% dispersion in oil). After 15 min, was added 4-[(6-chloropyridin-3-yl)methyl]morpholine (323 mg, 1.52 mmol; described in: Maienfisch, P. et al. J. Med. Chem. 2000, 43, 5003) to the solution. The reaction mixture was heated at reflux for 1 h. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate and water. A 2 M aqueous HCl solution was added to the ethyl acetate and water mixture until slightly acidic pH, and then NaHCO3 (s) was added until saturation. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried (Na2SO4) and the solvent was removed in vacuo. The crude product was dissolved in a mixture of methanol and ethyl acetate and was cooled on ice. A solution of HCl in diethyl ether was added until acidic pH. Approximately half of the solvent volume was removed in vacuo. The precipitated hydrochloride salt was filtered, washed with ethyl acetate, and dried in vacuo. The salt was converted back to the base by partitioning between ethyl acetate and an aqueous saturated NaHCO3 solution. The obtained material (142 mg) was purified on a silica gel column using chloroform/ethanol, (9:1), as the eluent affording 34 mg (7% yield) of the title compound as the base as a yellow solid: 1H NMR (CDCl3, 400 MHz) δ 14.96 (br s, 1H), 8.83 (br s, 1H), 7.79 (dd, J=9, 1 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.50 (d, J=9 Hz, 1H), 7.29-7.26 (m, 1H), 7.06 (d, J=8 Hz, 1H), 3.75-3.72 (m, 4H), 3.44 (s, 2H), 2.50-2.49 (m, 4H).
  • The base was dissolved in a mixture of methanol, dichloromethane, and ethyl acetate (15 mL total volume) and cooled on ice. A solution of HCl in diethyl ether (1 M) was added until acidic pH. Approximately half of the solvent volume was removed in vacuo, and ethyl acetate was added. The precipitated hydrochloride salt was filtered, washed with ethyl acetate, and dried in vacuo at 40° C. affording 33 mg (87% yield from the base) as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 14.75 (br s, 1H), 11.36 (br s, 1H), 10.98 (s, 1H), 8.30 (s, 1H), 8.07-8.02 (m, 2H), 7.90 (d, J=9 Hz, 1H), 7.32 (d, J=8 Hz, 1H), 7.02 (d, J=8 Hz, 1H), 4.29 (s, 2H), 3.98-3.94 (m, 2H), 3.82-3.75 (m, 2H), 3.37-3.32 (m, 2H), 3.11-3.08 (m, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 168.9, 148.4, 142.6, 139.7, 137.4, 124.8, 124.8, 120.8, 119.4, 118.4, 113.1, 108.9, 101.5, 85.6, 63.0, 55.5, 50.2; MS (TSP) m/z 335 (M++1).
    • Example 53 2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1H-indole-5-carbonitrile
  • To a solution of 5-cyanooxindole (411 mg, 2.60 mmol) in N,N-dimethylformamide (4 mL) was added sodium hydride (181 mg, 4.52 mmol, 60% dispersion in oil). After 10 min, a solution of 4-{2-[(6-chloropyrimidin-4-yl)oxy]ethyl}morpholine (367 mg, 1.51 mmol) in N,N-dimethylformamide (1.5 mL) was added dropwise. The mixture was stirred at room temperature for 3 h. The solvent was removed in vacuo, and the residue was suspended in a 2 M aqueous HCl solution and washed twice with ethyl acetate. The aqueous layer was alkalized to pH 8 by adding a 45% aqueous NaOH solution. The obtained suspension was extracted twice with ethyl acetate. The combined phases were washed with brine, dried (Na2SO4) and the solvent was removed in vacuo. The crude product was purified on a silica gel column using chloroform/ethanol, (9:1), to chloroform/methanol, (8:2), as the eluent affording 172 mg (31% yield) of the title compound as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 10.89 (br s, 1H), 8.62 (s, 1H), 8.02 (s, 1H), 7.30 (d, J=7 Hz, 1H), 6.97 (d, J=8 Hz, 1H), 6.83 (br s, 1H), 4.52 (t, J=5 Hz, 2H), 3.60 (t, J=4 Hz, 4H), 2.77 (m, 2H), 2.54 (m, 4H); MS (TSP) m/z 366 (M++1).
    • Example 54 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • A mixture of 5-cyanooxindole (694 mg, 4.39 mmol) and sodium hydride (234 mg, 5.85 mmol, 60% dispersion in oil) in N,N-dimethylformamide (2.5 mL) was stirred at room temperature for 15 min. To the greenish solution was added a solution of 1-[(6-chloropyridin-3-yl)methyl]-4-methylpiperazine (330 mg, 1.46 mmol) in N,N-dimethylformamide (1.2 mL) and the mixture was heated at 150° C. for 30 min. The mixture was allowed to cool and the solvent was removed in vacuo. The residue was suspended in a 2 M aqueous HCl solution and washed twice with ethyl acetate. The aqueous layer was alkalized with NaHCO3 (s) until saturation followed by three extractions with ethyl acetate. The organic layers were combined, dried (Na2SO4), and the solvent was removed in vacuo. The obtained material was purified twice by column chromatography on silica using chloroform/methanol/conc. NH3(aq), (90:10:0.5), as the eluent affording 56 mg of an oil. 38 mg of the oil was purified by preparative HPLC (column: Xterra, 19×300 mm, eluent: 0.05 M NH4OAc buffert/acetonitrile, 9:1-3:7) affording 29 mg (6% yield) of the title compound as a yellow solid: mp decomposes>240° C.; 1H NMR (CDCl3, 400 MHz) δ 8.74 (s, 1H), 7.78 (d, J=9 Hz, 1H), 7.70 (s, 1H), 7.64 (s, 1H), 7.50 (d, J=9 Hz, 1H), 7.29 (m, 1H), 7.06 (d, J=8 Hz, 1H), 3.44 (s, 2H), 2.52 (br s, 8H), 2.31 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 169.1, 149.6, 141.7, 136.1, 134.2, 125.4, 124.7, 123.6, 121.0, 119.7, 118.4, 109.3, 103.2, 85.4, 59.0, 55.0, 52.9, 45.9.
  • 10 mg of the solid was dissolved in a mixture of ethyl acetate, methylene chloride, and a small volume of methanol (10 mL total volume). The solution was cooled on ice and HCl in diethyl ether (1 M) was added until acidic pH. Approximately ⅔ of the solvent volume was removed in vacuo and ethyl acetate was added. The precipitated hydrochloride salt was filtered, washed with ethyl acetate and dried in vacuo affording 12 mg of the title compound as an orange solid: 1H NMR (D2O, 400 MHz) δ 7.78 (s, 1H), 7.68-7.65 (m, 1H), 7.47 (s, 1H), 7.34-7.31 (m, 1H), 7.14-7.11 (m, 1H), 6.93-6.6.90 (m, 1H), 3.62-3.48 (m, 10H), 2.77 (s, 3H); MS (TSP) m/z 348 (M++1).
    • Example 55 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide hydrochloride
  • A mixture of sodium hydride (330 mg, 8.2 mmol, 60% dispersion in oil, pre-washed with hexane) in N,N-dimethylformamide (2 mL) was added to 5-cyanooxindole (980 mg, 6.2 mmol) in N,N-dimethylformamide (4 mL). The formed brown mixture was stirred at room temperature for 20 min and 6-chloro-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide (500 mg, 2.1 mmol) in N,N-dimethylformamide (3 mL) was added. The obtained red solution was heated at 150° C. for 30 min and was then allowed to reach room temperature overnight. The solvent was removed in vacuo and the residue was partitioned between a 2 M aqueous HCl solution and ethyl acetate. The mixture was alkalized to pH 8 by adding NaHCO3 (s) and extracted with ethyl acetate. The combined extracts were dried (Na2SO4) and the solvent was removed in vacuo to afford 450 mg of a crude product. The residue was purified on a silica gel column using chloroform methanol/conc. NH3(aq), (80:19:1), as the eluent. Fractions containing product were collected, evaporated in vacuo and dried at 25° C. in vacuo to afford 70 mg. The residue was purified by preparative HPLC (column: Xterra, 19×300 mm, eluent: 0.05 M NH4OAc buffert/acetonitrile, 9:1-3:7). Fractions containing product were collected, evaporated in vacuo and dried at 25° C. in vacuo to afford 35 mg (4.6% yield) of the title compound as the base: 1H NMR (D2O, 400 MHz) δ 7.89 (s, 1H), 7.59 (d, J=9 Hz, 1H), 6.96 (s, 1H), 6.92 (d, J=8 Hz, 1H), 6.84 (d, J=9 Hz, 1H), 6.65 (d, J=8 Hz, 1H), 3.76 (s, 2H), 3.30 (s, 2H), 3.07 (s, 3H), 2.84 (s, 6H).
  • 10 mg of the base was dissolved in diethyl ether and treated with 5 M HCl in diethyl ether. The hydrochloride salt was dried at 25° C. in vacuo to afford 6 mg of the title compound as an orange powder: MS (ESP) m/z 364 (M++1).
    • Example 56 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • The reaction was performed as described in Example 55 using 1-(6-chloropyridine-3-sulfonyl)-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203). Yield: 9.8%: 1H NMR (D2O, 400 MHz) δ 8.12 (s, 1H), 7.60 (d, J=10 Hz, 1H), 7.13 (s, 1H), 7.00 (dd, J=8, 2 Hz, 1H), 6.93 (d, J=9 Hz, 1H), 6.73 (dd, J=8, 2 Hz, 1H), 3.91 (d, J=13 Hz, 2H), 3.60 (d, J=11 Hz, 2H), 3.24 (app. t, J=11 Hz, 2H), 3.02 (app. t, J=12 Hz, 2H), 2.89 (s, 3H); MS (TSP) m/z 398 (M++1).
    • Example 57 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide Hydrochloride
  • The reaction was performed as described in Example 55 using 6-chloro-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide. Purification on a silica gel column using chloroform/methanol/conc. NH3(aq), (80:19:1), as the eluent gave the title compound as the base.
  • Yields: 9.8%. 15 mg of the base was dissolved in methylene chloride/tetrahydrofuran/methanol (3 is mL total volume) and treated with 5 M HCl in diethyl ether. The hydrochloride salt was dried at 40° C. in vacuo to afford 11 mg of the title compound as an orange powder: 1H NMR (D2O, 400 MHz) δ 7.96 (s, 1H), 7.47 (d, J=9 Hz, 1H), 6.87 (s, 1H), 6.74 (d, J=8 Hz, 1H), 6.66 (d, J=9 Hz, 1H), 6.50 (d, J=8 Hz, 1H), 3.61 (m, 2H), 3.25 (m, 4H), 3.02 (m, 2H), 1.97 (m, 4H); MS (TSP) m/z 412 (M++1).
    • Example 58 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
  • To a suspension of sodium hydride (105 mg, 2.62 mmol, 60% in oil) in N,N-dimethylformamide (2 mL) was added 5-cyanooxindole (310 mg, 1.96 mmol). The mixture was stirred at room temperature for 10 min. To the obtained yellowish solution was added 2-chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide (299 mg, 1.31 mmol) and the mixture was heated under nitrogen at 130° C. for 30 min. The dark reaction mixture was allowed to cool and the solvent was removed in vacuo. The residue was partitioned between a 2 M aqueous solution of HCl and ethyl acetate. The aqueous layer was carefully saturated with NaHCO3 (s) and extracted twice with ethyl acetate. The two last organic layers were combined, dried (Na2SO4) and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (50 mL) and a concentrated solution of phosphorus trichloride (0.5 mL, 5.7 mmol) in ethyl acetate (3 mL) was added. A yellowish precipitate was formed. The mixture was stirred at room temperature overnight and then heated at 60° C. for 30 min and finally at reflux for 10 min. The mixture was allowed to cool and was then diluted with ethyl acetate and washed with a saturated aqueous NaHCO3 solution. The aqueous layer was extracted repeatedly with ethyl acetate. The combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo. The residue was purified on a silica gel column using chloroform/ethyl acetate, (9:1), as the eluent affording 195 mg (45% yield) of the title compound as a yellow solid: mp 228-230° C.; 1H NMR (DMSO-d6, 400 MHz) δ 14.79 (br s, 1H), 10.87 (s, 1H), 8.10 (s, 1H), 7.91 (s, 1H), 7.84 (d, J=9 Hz, 1H), 7.79 (dd, J=9, 1 Hz, 1H), 7.28 (d, J=8 Hz, 1H), 7.00 (d, J=8 Hz, 1H), 3.58 (t, J=4 Hz, 4H), 3.39 (s, 2H), 2.38 (br s, 4H); 13C NMR (DMSO-d6, 100 MHz) δ 168.6, 148.4, 142.0, 136.9, 135.9, 125.2, 124.0, 122.3, 121.0, 118.7, 118.3, 108.7, 101.2, 84.4, 66.1, 58.3, 52.8; MS (ESP) m/z 335 (M++1).
    • Example 59 2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride
  • To a suspension of sodium hydride (60% in mineral oil, 72 mg, 1.80 mmol) in N,N-dimethylformamide (1 mL) was added 5-cyanooxindole (213 mg, 1.35 mmol), and the mixture was stirred at ambient temperature for 15 min. To the obtained brownish solution was added a solution of 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine 1-oxide (191 mg, 0.90 mmol) in N,N-dimethylformamide (1.5 mL). The obtained red solution was heated at 125° C. for 20 min, and was then allowed to cool. The mixture was dissolved in 2 M HCl(aq) and washed with ethyl acetate. The organic layer was extracted with 2 M HCl(aq). The combined aqueous layers were alkalized to saturation with NaHCO3 (s), and extracted two times with ethyl acetate. The extracts were combined, dried (Na2SO4) and the solvent was removed in vacuo to give 270 mg of a crude product. The material was dissolved in ethyl acetate (15 mL), and a solution of phosphorus trichloride (0.25 mL, 2.87 mmol) in ethyl acetate (3 mL) was added. An orange precipitate was immediately formed. The mixture was heated at reflux for 30 min, and was then allowed to cool. The mixture was partitioned between ethyl acetate and a saturated aqueous NaHCO3 solution. The aqueous layer was extracted with another two portions of ethyl acetate. The combined organic layers were dried (Na2SO4) and the solvent was evaporated to give a crude product which was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (90:10:0.5), as the eluent affording 85 mg (37% yield) of the title compound as the free base as an orange solid: 1H NMR (CDCl3, 400 MHz) δ 14.9 (br s, 1H), 9.02 (s, 1H), 7.78 (dd, J=9, 2 Hz, 1H), 7.68 (s, 1H), 7.60 (s, 1H), 7.46 (d, J=9 Hz, 1H), 7.25-7.22 (m, 1H), 7.05 (d, J=8 Hz, 1H), 3.56 (s, 2H), 2.55-2.51 (m, 4H), 1.83-1.79 (m, 4H); MS (ES) m/z 319 (M++1). The base (65 mg) was dissolved in a mixture of ethyl acetate (20 mL), methylene chloride (10 mL), and methanol (2 mL), and was then cooled on an ice-bath. A solution of HCl in diethyl ether (1 M) was added until acidic pH. About 60% of the solvent volume was evaporated and to the residual suspension was added ethyl acetate. The obtained orange hydrochloride was filtered, washed with ethyl acetate, and dried in vacuo at 40° C. affording 65 mg (95% yield from the base) of the title compound as a brownish solid: 1H NMR (DMSO-d6, 400 MHz) δ 14.70 (br s, 1H), 11.00 (br s, 1H), 10.97 (s, 1H), 8.31 (s, 1H), 8.07 (dd, J=9, 1 Hz, 1H), 8.02 (s, 1H), 7.91 (d, J=8 Hz, 1H), 7.32 (d, J=7 Hz, 1H), 7.02 (d, J=7 Hz, 1H), 4.29 (d, J=6 Hz, 2H), 3.45-3.39 (m, 2H), 3.09-3.02 (m, 2H), 2.04-1.98 (m, 2H), 1.92-1.87 (m, 2H).
    • Example 60 2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • To a suspension of sodium hydride (60% in mineral oil, 263 mg, 6.58 mmol) in N,N-dimethylformamide (3 mL) was added 5-cyanooxindole (0.78 g, 4.94 mmol) in portions. The mixture was stirred at ambient temperature for 10 min. To the obtained brownish solution was added a solution of 1-[(6-chloro-1-oxidopyridin-3-yl)methyl]-4-methyl-1,4-diazepane (842 mg, 3.29 mmol) in N,N-dimethylformamide (3 mL). The reaction mixture was heated at 130° C. under a nitrogen atmosphere for 30 min. The dark mixture was allowed to cool and the solvent was removed in vacuo. To the residual oil was added 2 M HCl(aq) and the obtained suspension was washed twice with ethyl acetate. The aqueous layer was neutralized with 45% NaOH and alkalized to saturation with NaHCO3 (s), and extracted two times with ethyl acetate, and once with tetrahydrofuran. The extracts were combined, dried (Na2SO4) and the solvent was removed in vacuo affording 1.0 g of the crude N-oxide: MS (ES) m/z 278 (M++1). Part of the material (841 mg, 2.23 mmol) was dissolved in acetonitrile (70 mL) during heating. To the warm solution was added phosphorus trichloride (1 mL, 11.1 mmol), dropwise initially and then at a faster rate. The obtained orange suspension was heated at reflux for 1 h, and was then allowed to cool. The precipitate was filtered, washed with acetonitrile, and dried in vacuo affording 780 mg of an orange residue. Part of the material (240 mg) was dissolved in H2O, NaHCO3 (s) was added until saturation, and the mixture was extracted three times with ethyl acetate and once with tetrahydrofuran. The combined organic layers were dried (Na2SO4 and MgSO4), and the solvent was evaporated to give 165 mg of an oil which was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (80:20:1), as the eluent to give 84 mg of the title compound as the free base as a brownish solid: 1H NMR (DMSO-d6, 400 MHz) δ 14.70 (br s, 1H), 10.79 (br s, 1H), 8.11 (s, 1H), 7.92 (s, 1H), 7.87 (d, J=9 Hz, 1H), 7.79 (d, J=8 Hz, 1H), 7.25 (d, J=7 Hz, 1H), 6.98 (d, J=7 Hz, 1H), 3.53 (s, 2H), 2.69-2.57 (m, 8H), 2.30 (s, 3H), 1.78-1.70 (m, 2H). The base (66 mg) was converted to the hydrochloride using the method described for Example 59. Yield: 99% (calculated from the base) of the title compound as an orange solid: 1H NMR (D2O, 400 MHz) δ 7.91 (s, 1H), 7.65 (dd, J=9, 2 Hz, 1H), 7.01-6.95 (m, 3H), 6.74 (d, J=7 Hz, 1H), 4.32 (s, 2H), 3.80-3.54 (m, 8H), 2.97 (s, 3H), 2.31 (br s, 2H).
  • The following Examples, 61-62, were prepared as described for Example 60:
    • Example 61 2-Hydroxy-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • Starting material: 2-chloro-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridine 1-oxide. The product was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (90:10:0.5), as the eluent. Yield: 15% of the title compound as the base as an orange solid: 1H NMR (CDCl3, 400 MHz) δ 8.75 (br s, 1H), 7.76 (dd, J=9, 2 Hz, 1H), 7.69 (s, 1H), 7.64 (s, 1H), 7.49 (d, J=9 Hz, 1H), 7.29-7.25 (m, 1H), 7.05 (d, J=8 Hz, 1H), 3.41 (s, 2H), 2.88 (d, J=11 Hz, 2H), 2.58 (br s, 4H), 2.11-1.99 (m, 3H), 1.90 (d, J=12 Hz, 2H), 1.80 (br s, 4H), 1.65-1.53 (m, 2H); MS (ES) m/z 402 (M++1). The base (72 mg) was dissolved in a mixture of ethyl acetate (5 mL), methylene chloride (10 mL), and was then cooled on an ice-bath. A solution of HCl in diethyl ether was (1 M) added until acidic pH. The obtained orange hydrochloride was filtered, washed with ethyl acetate, and dried in vacuo at room temperature affording 68 mg (80% yield, calculated from the base) of the title compound as an orange solid: 1H NMR (D2O, 400 MHz) δ 7.90 (s, 1H), 7.71 (d, J=9 Hz, 1H), 7.25 (s, 1H), 7.15 (d, J=9 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 6.89 (d, J=8 Hz, 1H), 4.00 (br s, 2H), 3.55-3.41 (m, 5H), 2.92-2.82 (m, 2H), 2.43 (d, J=13 Hz, 2H), 2.09 (br s, 4H), 1.98-1.87 (m, 2H).
    • Example 62 3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: 1-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N,N-dimethylpyrrolidin-3-amine. The crude product was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (85:15:1), as the eluent. The obtained material was purified further by preparative HPLC (column: Xterra, C8, 7 μm, 19×300 mm; eluent: 0.1 M NH4OAc buffer/acetonitrile, 8:2 to 4:6) affording the title compound as an orange solid. Yield: 6%: 1H NMR (CDCl3, 400 MHz) δ 9.12 (br s, 1H), 7.77 (d, J=9 Hz, 1H), 7.71 (s, 1H), 7.63 (s, 1H), 7.49 (d, J=9 Hz, 1H), 7.28-7.24 (m, 1H), 7.06 (d, J=8 Hz, 1H), 3.60-3.48 (m, 2H), 2.95-2.89 (m, 1H), 2.82-2.76 (m, 1H), 2.72-2.68 (m, 1H), 2.64-2.58 (m, 1H), 2.53-2.48 (m, 1H), 2.27 (s, 6H), 2.09-2.00 (m, 1H), 1.87-1.79 (m, 1H); MS (ES) m/z 362 (M++1).
    • Example 63 2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile
  • To a suspension of sodium hydride (60% in mineral oil, 54 mg, 1.35 mmol) in N,N-dimethylformamide (1 mL) was added 5-cyanooxindole (161 mg, 1.02 mmol), and the mixture was stirred at ambient temperature for 10 min. To the obtained brownish solution was added a solution of 2-chloro-5-[(4-methylpiperidin-1-yl)methyl]pyridine 1-oxide (163 mg, 0.677 mmol) in N,N-dimethylformamide (1.5 mL). The reaction mixture was heated at 130° C. for 25 min, and was then allowed to cool. The solvent was removed in vacuo, and to the residue was added 2 M HCl(aq). The obtained precipitate was partitioned between a saturated aqueous NaHCO3 solution and ethyl acetate. The aqueous layer was extracted with another two portions of ethyl acetate. The combined organic layers were dried (Na2SO4), and the solvent was removed in vacuo affording a crude product. The material was dissolved in ethyl acetate (25 mL), and phosphorus trichloride (0.24 mL, 2.71 mmol) was added. An orange precipitate was immediately formed. The mixture was heated at reflux for 30 min, and was then allowed to cool. The mixture was partitioned between ethyl acetate and a saturated aqueous NaHCO3 solution. The aqueous layer was extracted with another portion of ethyl acetate. The combined organic layers were dried (Na2SO4), and the solvent was evaporated. The crude product was purified on a silica gel column using chloroform/methanol, (95:5), as the eluent followed by preparative HPLC (column: Xterra, C8, 7 μm, 19×300 mm; eluent: 0.1 M NH4OAc buffer/acetonitrile, 8:2 to 4:6) affording 4 mg (2% yield) of the title compound as an orange solid: 1H NMR (acetone-d6, 400 MHz) δ 9.88 (br s, 1H), 8.11 (d, J=1 Hz, 1H), 7.90 (dd, J=9, 2 Hz, 1H), 7.85 (d, J=9 Hz, 1H), 7.82 (d, J=1 Hz, 1H), 7.26 (dd, J=8, 2 Hz, 1H), 7.11 (d, J=8 Hz, 1H), 3.44 (s, 2H), 2.91-2.86 (m, 2H), 2.10-1.98 (m, 2H), 1.65-1.59 (m, 2H), 1.40-1.35 (m, 1H), 1.28-1.16 (m, 2H), 0.92 (d, J=7 Hz, 3H); MS (ES) m/z 347 (M++1).
    • Example 64 2-Hydroxy-3-{5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile
  • To a suspension of sodium hydride (60% dispersion in mineral oil, 45 mg, 1.12 mmol) in N,N-dimethylformamide (1 mL) was added 5-cyanooxindole (133 mg, 0.84 mmol). The mixture was stirred for 15 min, and a suspension of 1-[(6-chloro-1-oxidopyridin-3-yl)methyl]-4-phenylpiperazine (0.56 mmol) in N,N-dimethylformamide (2.3 mL) was added. The reaction mixture was heated at 130° C. for 10 min and was then allowed to cool to room temperature. The dark reaction mixture was acid/base-extracted using an Allex robot. The following steps were included: addition of HCl (aq), washing with ethyl acetate (to remove excess of 5-cyanooxindole), alkalization with (sat) NaHCO3, and finally repeated extractions with ethyl acetate. The combined organic extracts were dried (Na2SO4), and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (10 mL), and phosphorus trichloride (0.2 mL, 2.24 mmol) was added. The resulting suspension was stirred at ambient temperature for 1.5 h, and then heated at reflux for 30 min. The reaction mixture was allowed to cool to room temperature. The mixture was washed with a saturated aqueous NaHCO3 solution using an Allex robot. The aqueous layer was repeatedly extracted with ethyl acetate. The combined organic layers were dried (Na2SO4), and the solvent was evaporated to give 20 mg of an orange product which was purified on silica using chloroform/ethanol, (95:5), as the eluent. The obtained material (10 mg) was purified further by preparative HPLC (column: Xterra, C8, 7 μm, 19×300 mm; eluent: 0.1 M NH4OAc buffer/acetonitrile, 8:2 to 4:6) affording 5 mg (1.1% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 14.78 (br s, 1H), 10.86 (s, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.86-7.82 (m, 2H), 7.27 (d, J=8 Hz, 1H), 7.23-7.16 (m, 2H), 7.00 (d, J=8 Hz, 1H), 6.93 (d, J=8 Hz, 2H), 6.77 (t, J=7 Hz, 1H), 3.46 (s, 2H), 3.16-3.12 (m, 4H), 2.57-2.53 (m, 4H); MS (ES) m/z 410 (M++1).
  • The following Examples, 65-70, were prepared as described for Example 64:
    • Example 65 3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: 5-(azetidin-1-ylmethyl)-2-chloropyridine 1-oxide. The title compound was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (90:10:0.5). Yield: 1%: 1H NMR (acetone-d6, 400 MHz) δ 9.86 (br s, 1H), 8.10 (s, 1H), 7.86-7.83 (m, 2H), 7.81 (d, J=2 Hz, 1H), 7.26 (dd, J=8, 2 Hz, 1H), 7.11 (d, J=8 Hz, 1H), 3.51 (d, J=1 Hz, 2H), 3.22 (t, J=7 Hz, 4H); MS (ES) m/z 305 (M++1).
    • Example 66 2-Hydroxy-3-[5-({4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)pyridin-2-yl]-1H-indole-5-carbonitrile
  • Starting material: 1-[(6-chloro-1-oxidopyridin-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine. Yield: 1%: 1H NMR (DMSO-d6, 400 MHz) δ 14.79 (br s, 1H), 10.85 (s, 1H), 8.15-8.12 (m, 2H), 7.90 (s, 1H), 7.87-7.80 (m, 3H), 7.43 (d, J=9 Hz, 1H), 7.27 (d, J=8 Hz, 1H), 7.00 (d, J=8 Hz, 1H), 3.47 (s, 2H), 3.17-3.14 (m, 4H), 2.55-2.52 (m, 4H); MS (ES) m/z 523 (M++1).
    • Example 67 3-(5-{[(2-Cyanoethyl)(ethyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: 3-[[(6-chloro-1-oxidopyridin-3-yl)methyl](ethyl)amino]propanenitrile. Yield: 1%: 1H NMR (DMSO-d6, 400 MHz) δ 14.80 (br s, 1H), 10.84 (s, 1H), 8.11 (s, 1H), 7.93 (s, 1H), 7.86 (d, J=9 Hz, 1H), 7.83 (d, J=9 Hz, 1H), 7.26 (d, J=8 Hz, 1H), 6.99 (d, J=8 Hz, 1H), 3.52 (s, 2H), 2.73-2.70 (m, 2H), 2.69-2.65 (m, 2H), 2.53 (q, J=7 Hz, 2H), 1.00 (t, J=7 Hz, 3H); MS (ES) m/z 346 (M++1).
    • Example 68 3-(5-{[(4-Chlorobenzyl)(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: N-(4-chlorobenzyl)-N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methylamine. Yield: 1%: 1H NMR (DMSO-d6, 400 MHz) δ 14.79 (br s, 1H), 10.85 (s, 1H), 8.15 (s, 1H), 7.90 (s, 1H), 7.85-7.82 (m, 2H), 7.41-7.36 (m, 4H), 7.27 (d, J=8 Hz, 1H), 7.00 (d, J=8 Hz, 1H), 3.52 (s, 2H), 3.44 (s, 2H), 2.11 (s, 3H); MS (ES) m/z 401 (M++1).
    • Example 69 3-(5-{[(2-Furylmethyl)(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-(2-furylmethyl)-N-methylamine. Yield: 4%: 1H NMR (DMSO-d6, 400 MHz) δ 14.80 (br s, 1H), 10.86 (s, 1H), 8.10 (s, 1H), 7.91 (s, 1H), 7.85 (d, J=9 Hz, 1H), 7.79 (d, J=9 Hz, 1H), 7.61 (d, J=1 Hz, 1H), 7.27 (d, J=8 Hz, 1H), 7.00 (d, J=8 Hz, 1H), 6.43 (dd, J=3, 2 Hz, 1H), 6.34 (d, 3 Hz, 1H), 3.59 (s, 2H), 3.42 (s, 2H), 2.15 (s, 3H); MS (ES) m/z 359 (M++1).
    • Example 70 2-Hydroxy-3-(5-{[methyl(phenyl)amino]methyl}pyridin-2-yl)-1H-indole-5-carbonitrile
  • Starting material: N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methyl-N-phenylamine. The product was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (90:10:0.5), as the eluent. Yield 2%: 1H NMR (DMSO-d6, 400 MHz) δ 10.82 (br s, 1H), 8.06 (s, 1H), 7.91-7.68 (m, 3H), 7.26-7.23 (m, 1H), 7.22-7.16 (m, 2H), 7.00-6.96 (m, 1H), 6.80 (d, J=8 Hz, 2H), 6.66 (t, J=7 Hz, 1H), 4.49 (s, 2H), 2.98 (s, 3H); MS (ES) m/z 353 (M+−1).
    • Example 71 2-Hydroxy-3-{5-[(3-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile
  • To a suspension of sodium hydride (60% in mineral oil, 45 mg, 1.12 mmol) in N,N-dimethylformamide (1 mL) was added 5-cyanooxindole (133 mg, 0.84 mmol), and the mixture was stirred at ambient temperature for 10 min. To the obtained brownish solution was added a solution of 2-chloro-5-[(3-methylpiperidin-1-yl)methyl]pyridine 1-oxide (0.56 mmol) in N,N-dimethylformamide (1.5 mL). The reaction mixture was heated at 130° C. for 30 min, and was then allowed to cool. To the residue was added 2 M HCl(aq) and the obtained suspension was washed with ethyl acetate. The aqueous layer was neutralized with 45% NaOH(aq) and alkalized to saturation with NaHCO3 (s), and extracted two times with ethyl acetate. The extracts were combined, dried (MgSO4) and the solvent was removed in vacuo affording 84 mg of the crude product. The material was dissolved in ethyl acetate (10 mL), and to the solution was added phosphorus trichloride (0.2 mL, 2.24 mmol). The obtained orange suspension was heated at reflux for 1 h and was then allowed to cool. The precipitate was filtered, washed with ethyl acetate, and dried in vacuo affording 70 mg of an orange residue. The material was purified by preparative HPLC (column: Xterra, C8, 7 μm, 19×300 mm; eluent: 0.1 M NH4OAc buffer/acetonitrile, 8:2 to 4:6) affording 15 mg (8% yield) of the title compound as an orange solid: 1H NMR (acetone-d6, 400 MHz) δ 9.86 (br s, 1H), 8.11 (s, 1H), 7.91 (dd, J=9, 2 Hz, 1H), 7.84 (d, J=9 Hz, 1H), 7.82 (d, J=1 Hz, 1H), 7.26 (dd, J=8, 2 Hz, 1H), 7.11 (d, J=8 Hz, 1H), 3.44 (s, 2H), 2.00-1.50 (m, 6H), 0.95-0.81 (m, 4H); MS (ES) m/z 347 (M++1).
  • The following Examples, 72-73, were prepared as described for Example 71:
    • Example 72 3-(5-{[Cyclohexyl(methyl)amino]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile
  • Starting material: N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-cyclohexyl-N-methylamine. Yield: 3%: 1H NMR (CDCl3, 400 MHz) δ 8.64 (br s, 1H), 7.79 (dd, J=9, 2 Hz, 1H), 7.75 (s, 1H), 7.68 (s, 1H), 7.53 (d, J=9 Hz, 1H), 7.30 (dd, J=8, 1 Hz, 1H), 7.05 (d, J=8 Hz, 1H), 3.52 (s, 2H), 2.23 (s, 3H), 1.88-1.80 (m, 5H), 1.36-1.02 (m, 6H); MS (ES) m/z 361 (M++1).
    • Example 73 2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
  • Starting material: 2-chloro-5-(piperidin-1-ylmethyl)pyridine 1-oxide. Yield: 4%: 1H NMR (acetone-d6, 400 MHz) δ 9.85 (br s, 1H), 8.11 (s, 1H), 7.91 (dd, J=9, 2 Hz, 1H), 7.85 (d, J=9 Hz, 1H), 7.82 (d, J=1 Hz, 1H), 7.26 (dd, J=8, 2 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 3.43 (s, 2H), 2.47-2.41 (m, 4H), 1.61-1.54 (m, 4H), 1.49-1.41 (m, 2H); MS (ES) m/z 333 (M++1).
    • Example 74 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol Hydrochloride
  • Sodium hydride (46 mg, 60% dispersion in paraffin) was washed with hexane and dried in vacuo. N,N-Dimethylformamide (3 mL), oxindole (72 mg, 0.54 mmol) and 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (100 mg, 0.36 mmol; described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) were added to the sodium hydride and the reaction mixture was stirred at room temperature for 5 min. The reaction mixture was then heated for 10 min at 130° C. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution was added. The mixture was extracted twice with methylene chloride and the combined organic layers were dried (Na2SO4), filtrated and the solvent was removed in vacuo. The residue was purified on a silica gel column using a gradient ethyl acetate/methanol, (40:1 to 1:1), as the eluent. The product was dissolved in a mixture of methylene chloride (5 mL) and methanol (5 mL). Hydrogen chloride (3 mL, 1 M in diethyl ether) was added and stirring was continued for 10 min. The precipitate was washed with diethyl ether and dried in vacuo to give 50 mg (37% yield) of the title compound: 1H NMR (D2O, 400 MHz) δ 7.95 (m, 1H), 7.45 (d, J=2 Hz, 1H), 7.43 (dd, J=9, 2 Hz, 1H), 7.23 (m, 1H), 7.14 (d, J=9 Hz, 1H), 7.00 (m, 2H), 3.88 (d, J=14 Hz, 2H), 3.60 (d, J=12 Hz, 2H), 3.23 (m, 2H), 2.94 (m, 2H), 2.90 (s, 3H); MS (ES) m/z 373 (M++1).
    • Example 75 6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 74 using 6-chlorooxindole. The base was purified on a silica gel column using a gradient chloroform/methanol, (100:0 to 4:1), as the eluent. The product was dissolved in a mixture of chloroform (10 mL) and methanol (10 mL). Hydrogen chloride (3 mL, 1 M in diethyl ether) was added and stirring was continued for 10 min. The precipitate was washed with diethyl ether and dried in vacuo to give 50 mg (29% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 10.95 (m, 1H), 10.79 (s, 1H), 8.49 (s, 1H), 7.68 (m, 1H), 7.64 (m, 1H), 7.55 (d, J=8 Hz, 1H), 6.98 (m, 1H), 6.93 (m, 1H), 3.74 (m, 2H), 3.45 (m, 2H), 3.12 (m, 2H), 2.97 (m, 2H), 2.75 (m, 3H); MS (ES) m/z 407 (M++1).
    • Example 76 3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol
  • Ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (0.327 g, 1.0 mmol) was suspended in benzene (13 mL) followed by the addition of morpholine (0.218 g, 2.5 mmol). The mixture was stirred (N2 atmosphere) for 5 min at 0° C. To this mixture, trimethyl aluminum (2 M solution in hexane, 2 mL, 4 mmol) was added via a syringe. After 10 min the temperature was raised to 70° C. and the reaction mixture was stirred for 20 h then poured onto an ice-cold aqueous saturated NaHCO3 solution and extracted with chloroform. The combined organic layer was concentrated and the light brown residue was purified on a silica gel column using chloroform/methanol/triethylamine, (50:10:1), as eluent to give 0.22 g (60% yield) of the title compound: 1H NMR (acetone-d6, 400 MHz) δ 8.47 (s, 1H), 8.41 (s, H), 8.05 (d, J=8 Hz, 1H), 7.99 (d, J=8 Hz, 1H), 7.90 (d, J=8 Hz, 1H), 7.19 (d, J=8 Hz, 1H), 3.79 (br s, 2H), 3.73 (br s, 4H), 2.68 (br s, 4H); MS (EI) m/z 369 (M+1+).
    • Example 77 6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol Hydrochloride
  • To a N,N-dimethylformamide (1.5 mL) suspension of sodium hydride (60% dispersion in oil, 40 mg, 1.0 mmol, pre-washed with hexane) was added 6-bromoxindole (0.159 g, 0.75 mmol). The formed mixture was stirred for 5 min at room temperature followed by the addition of 2-chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide (0.114 g, 0.5 mmol). The resulting reaction mixture was stirred (N2 atmosphere) for 30 min at 120° C. The solvent was evaporated in vacuo and the residual oil was purified on a silica gel column using chloroform/methanol, (10:1), as eluent affording the N-oxide product. The N-oxide was dissolved in chloroform (3 mL) and phosphorus trichloride (0.412 g, 3.0 mmol) was added. The reaction mixture was stirred for 30 min at 60° C. and then cooled to room temperature. The mixture was quenched with methanol and concentrated. The residue was purified on a silica column using a chloroform/methanol gradient, (10:1 to 1:2), as the eluent to give 52 mg (4% yield) of the title compound as the base as brownish solid. The base (30 mg, 0.077 mmol) was dissolved in methylene chloride/methanol, (1:1), and treated with 1 M HCl in diethyl ether at 0° C. The resulting yellowish orange crystals were collected by filtration and washed with diethyl ether to give 5 mg (15% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 10.61 (s, 1H), 8.59 (br s, 1H), 8.23 (s, 1H), 7.96 (s, 1H), 7.70 (s, 1H), 7.54 (d, J=8 Hz, 1H), 7.09 (d, J=8 Hz, 1H), 7.05 (s, 1H), 4.17 (br s, 2H), 3.85 (br s, 4H), 3.10 (br s, 4H); MS (EI) m/z 388 (M), 390 (M++2).
    • Example 78 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile Hydrochloride
  • The title compound was prepared as described for Example 77 using 6-cyanooxindole. The base was obtained as a yellow solid after purification by preparative HPLC (column: Xterra, C8, 7 μm, 19×300 mm; eluent: 0.1 M NH4OAc buffer/acetonitrile, 8:2 to 4:6). Yield: 13%. The base was transformed to the yellow hydrochloride salt in 33% yield: 1H NMR (D2O, 400 MHz) δ 8.21 (s, 1H), 8.04 (d, J=8 Hz, 1H), 7.82 (d, J=8 Hz, 1H), 7.64 (d, J=8 Hz, 1H), 7.29 (s, 1H), 7.28 (d, J=8 Hz, 1H), 3.97 (s, 2H), 3.69 (br s, 4H), 2.65 (br s, 4H); MS (EI) m/z 335 (M++1).
    • Example 79 5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol Hydrochloride
  • To a N,N-dimethylformamide (3.0 mL) suspension of sodium hydride (60% dispersion in oil, is 0.480 g, 12.0 mmol, pre-washed with hexane) was added 5-bromooxindole (1.9 g, 9.0 mmol). The mixture was stirred for 10 min at 0° C. and for 5 min at room temperature. 2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide (1.37 g, 6.0 mmol) was added and the resulting reaction mixture was stirred (N2 atmosphere) for 50 min at 120° C., then cooled to room temperature. The N,N-dimethylformamide solution was diluted with an aqueous saturated NaHCO3 solution and NaCl (s, 2 g) was added followed by extraction with chloroform and ethyl acetate. The combined organic phases were dried (Na2SO4) and concentrated in vacuo. The remaining N,N-dimethylformamide was removed by co-evaporation with toluene two times. The residual oil was dissolved in chloroform (10 mL) and phosphorus trichloride (3.0 g, 21.8 mmol) was added. The reaction mixture was stirred for 30 min at 60° C. and then cooled to room temperature. The mixture was poured into an aqueous saturated NaHCO3 solution.
  • A brown precipitate was formed, which was filtered off, and the filtrate (containing some product) was treated separately (see bellow).
  • The brown solid was dissolved in methanol (150 mL) and insoluble materials were removed by filtration. This solution was concentrated to a brownish yellow solid, which was suspended in ethyl acetate (15 mL) and stirred overnight at room temperature. The yellow solid was collected by filtration and dried to afford 1.28 g of the product.
  • To the NaHCO3 solution (filtrate, see above), NaCl(s) (2.0 g) was added followed by extractions with chloroform and ethyl acetate. The combined organic phases were dried (Na2SO4) and concentrated in vacuo. The residue was purified on a silica gel column using chloroform/methanol, (5:1) as eluent. The residue was suspended in ethyl acetate (15 mL) and stirred overnight at room temperature. The solid was filtered, dried to give 90 mg of the title compound as a yellow solid as the base. The obtained total amount of the base was 1.37 g (59% yield). A small amount of the free base (12 mg, 0.03 mmol) was dissolved in methylene chloride/methanol, (1:1) and treated with 1 M HCl in diethyl ether at 0° C. The resulting yellow crystals were collected by filtration and washed with diethyl ether to obtain 13 mg (100% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 10.52 (s, 1H), 8.09 (s, 1H), 7.81 (d, J=8 Hz, 1H), 7.70 (d, J=8 Hz, 1H), 7.61 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.86 (d, J=8 Hz, 1H), 3.62 (br s, 4H), 3.40 (s, 2H), 2.42 (br s, 4H); MS (EI) m/z 388 (M+), 390 (M++2).
    • Example 80 5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 79 using 5,6-dibrom-1,3-dihydro-indol-2-one. The base (27% yield) was transformed to the hydrochloride salt. The salt was purified by re-crystallization from chloroform/methanol/diethyl ether and the crystals were washed with dimethylsulfoxide (1 mL) to give the title compound. Yield: 4%: 1H NMR (CDCl3, 400 MHz) δ 8.29 (s, 1H), 7.75 (d, J=10 Hz, 1H), 7.68 (s, 1H), 7.62 (s, 1H), 7.47 (d, J=10 Hz, 1H), 7.21 (s, 1H), 3.72 (br s, 4H), 3.40 (s, 2H), 2.48 (br s, 4H).
    • Example 81 3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile Hydrochloride
  • 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile (0.10 g, 0.3 mmol) was dissolved in tetrahydrofuran/dioxane, (1:1, 16 mL), under N2 atmosphere and stirred at −20° C. for 5 min. To this mixture, sodium bis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 0.30 mL, 0.3 mmol) was added via syringe and the reaction was allowed to stir for 20 min at ambient temperature. 1-Fluoro-2,4,6-trimethylpyridinium triflate (0.112 g, 0.33 mmol) was added and the reaction was allowed to warm to room temperature and stirred for 16 h. The solvent was removed in vacuo and the residue was taken up in ethyl acetate and washed with an aqueous saturated NaHCO3 solution. The organic phase was dried (Na2SO4) and evaporated in vacuo. The crude product was purified by preparative HPLC (column: Xterra, C8, 10 μm, 19×300 mm; eluent: 0.05 M NH4OAc buffer/acetonitrile, 8:2-2:8) affording 50 mg (47% yield) of a yellowish brown solid. The solid (40 mg, 0.11 mmol) was dissolved in methylene chloride/methanol, (1:1), and treated with 1 M HCl in diethyl ether at 0° C. The resulting yellow crystals were collected by filtration and washed with diethyl ether to give 18 mg (42% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 8.42 (s, 1H), 7.96 (d, J=8 Hz, 1H), 7.83 (d, J=8 Hz, 1H), 7.50 (d, J=8 Hz, 1H), 7.46 (d, J=8 Hz, 1H), 7.44 (s, 1H), 3.60 (br s, 4H), 3.54 (s, 2H), 2.38 (br s, 4H): MS (EI) m/z 353 (M++1).
    • Example 82 3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile Hydrochloride
  • To a suspension of sodium hydride (0.09 g, 2.2 mmol, 60% dispersion in oil, pre-washed with hexane) in N,N-dimethylformamide (3 mL), cooled on an ice-bath, was added a solution of 5-cyanooxindole (0.32 g, 2.0 mmol) in N,N-dimethylformamide (3 mL). The mixture was stirred for 20 min under a nitrogen atmosphere and the ice-bath was removed. 1-Benzyl-4-[(6-chloropyridine-3-yl)sulfonyl]piperazine (0.35 g, 1.0 mmol), dissolved in N,N-dimethylformamide (4 mL), was added dropwise and the mixture was heated at 130° C. for 40 min. The solvent was evaporated in vacuo and the residue was partitioned between methylene chloride and aqueous NaHCO3 (pH>7). The mixture was extracted with methylene chloride. The organic layers were combined, dried (Na2SO4) and the solvent was removed in vacuo. The crude product was purified on a silica gel column using chloroform/ethanol, (20:1), as the eluent. The base (120 mg) was dissolved in chloroform/methanol and a solution of HCl in diethyl ether (1 M) was added until acidic pH. The formed precipitation was filtered and washed with diethyl ether affording 71 mg (14% yield) of the title compound as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 11.15 (br s, 1H), 10.54 (br s, 1H), 8.54 (br s, 1H), 8.01 (br s, 1H), 7.88-7.81 (m, 1H), 7.70 (dd, J=9, 2 Hz, 1H), 7.56-7.47 (m, 2H), 7.47-7.38 (m, 4H), 7.06 (d, J=8 Hz, 1H), 4.40-4.28 (m, 2H), 3.83-3.66 (m, 2H), 3.23-3.04 (m, 4H), 3.04-2.88 (m, 2H); MS (ES) m/z 474 (M++1).
    • Example 83 2-Hydroxy-3-(5-{[4-(3-methylbutyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1H-indole-5-carbonitrile Hydrochloride
  • The title compound was prepared as described for Example 82 using 5-cyanooxindole and 1-[(6-chloropyridin-3-yl)sulfonyl]-4-(3-methylbutyl)piperazine. Yield: 5% of the title compound as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 1.15 (br s, 1H), 10.63 (br s, 1H), 8.57 (s, 1H), 8.02 (s, 1H), 7.94-7.81 (m, 1H), 7.73 (d, J=9 Hz, 1H), 7.41 (d, J=8 Hz, 1H), 7.05 (d, J=8 Hz, 1H), 3.82-3.67 (m, 2H), 3.62-3.34 (m, 2H), 3.20-2.92 (m, 6H), 1.64-1.46 (m, 3H), 0.86 (d, J=6 Hz, 6H); MS (ES) m/z 454 (M++1).
    • Example 84 2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile Hydrochloride
  • The title compound was prepared as described for Example 82 using 5-cyanooxindole and 1-[(6-chloropyridin-3-yl)sulfonyl]-4-isopropylpiperazine. Yield: 30% of the title compound as a yellow solid; 1H NMR (DMSO-d6, 400 MHz) δ 11.56 (br s, 1H), 10.68 (br s, 1H), 8.57 (br s, 1H), 8.02 (s, 1H), 7.93-7.81 (m, 1H), 7.74 (dd, J=9, 2 Hz, 1H), 7.42 (dd, J=8, 1 Hz, 1H), 7.06 (d, J=8 Hz, 1H) 3.82-3.71 (m, 2H), 3.58-3.31 (m, 3H), 3.24-1.82 (m, 4H), 1.24 (d, J=7 Hz, 6H); MS (ES) m/z 304 (M++1).
    • Example 85 3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile Hydrochloride
  • The title compound was prepared as described for Example 82 using 5-cyanooxindole and 1-[(6-chloropyridin-3-yl)sulfonyl]-4-ethylpiperazine. Yield: 4% of the title compound as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 11.15 (br s, 1H), 10.75 (br s, 1H), 8.56 (br s, 1H), 8.04 (s, 1H), 7.93-7.82 (m, 1H), 7.73 (dd, J=9, 2 Hz, 1H), 7.41 (dd, J=8, 1 Hz, 1H), 7.05 (d, J=8 Hz, 1H), 3.83-3.69 (m, 2H), 3.69-3.42 (m, 2H), 3.18-2.92 (m, 6H), 1.20 (t, J=7.2 Hz, 3H); MS (ES) m/z 412 (M++1).
    • Example 86 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol
  • To a solution of 3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-pyridin-3-yl-1H-indol-2-ol (200 mg, 0.6 mmol) in ethyl acetate (60 mL) was added phosphorus trichloride (0.4 mL). A yellow precipitate was formed and the mixture was refluxed for 3 h, and then diluted with ethyl acetate and washed with an aqueous saturated NaHCO3 solution. The aqueous layer was extracted with two portions of ethyl acetate and one portion of chloroform. The organic layers were combined, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by preparative HPLC (column: Xterra, 19×300 mm, eluent: water/acetonitrile, (0:100 to 100:0), gradient) affording 6 mg (3% yield) of the title compound as a yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 10.50 (br s, 1H), 8.92 (d, J=2 Hz, 1H), 8.49 (dd, J=4, 1 Hz, 1H), 8.12-8.06 (m, 1H), 8.02 (s, 1H), 7.90-7.71 (m, 1H), 7.71-7.67 (m, 2H), 7.43 (dd, J=8, 5 Hz, 1H), 7.20 (d, J=8 Hz, 1H), 6.98 (d, J=8 Hz, 1H), 3.63-3.53 (m, 4H), 3.40-3.24 (m, 2H), 2.42-2.34 (m, 4H); MS (ES) m/z 388 (M++1).
    • Example 87 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 86 using 3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol and phosphorus trichloride. The base was dissolved in chloroform/methanol, (3:1), and a solution of HCl in diethyl ether (1 M) was added until acidic pH. The formed precipitation was filtered, washed with diethyl ether and dried. Yield: 9% of the title compound as an yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 11.10 (br s, 1H), 10.55 (s, 1H), 8.21 (s, 1H), 8.02-7.90 (m, 1H), 7.85-7.62 (m, 2H), 7.54-7.46 (m, 1H), 7.46-7.37 (m, 1H), 7.18 (d, J=8 Hz, 1H), 7.15-7.06 (m, 1H), 6.92 (d, J=8 Hz, 1H), 4.24 (s, 2H), 4.03-3.89 (m, 2H), 3.84-3.51 (m, 2H), 3.39-3.28 (m, 2H) 3.16-3.05 (m, 2H); MS (ES) m/s 392 (M++1).
    • Example 88 5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 86 using 5-(2-furyl)-3-[5-(morpholin-4-ylmethyl)-1-oxidopyridin-2-yl]-1H-indol-2-ol. Yield: 6% of the title compound as an yellow solid: 1H NMR (DMSO-d6, 400 MHz) δ 10.26 (br s, 1H), 10.56 (s, 1H), 8.22 (s, 1H), 8.03-7.94 (m, 1H), 7.83-7.71 (m, 2H), 7.66 (s, 1H), 7.30 (d, J=8 Hz, 1H), 6.98-6.86 (m, 2H), 6.59-6.53 (m, 1H), 4.31-4.10 (m, 2H), 4.16-3.85 (m, 2H), 3.85-3.70 (m, 2H), 3.39-3.26 (m, 2H), 3.17-3.01 (m, 2H); MS (ES) m/z 376 (M++1).
    • Example 89 3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 55 using 5-nitrooxindole and 1-1-[(5-bromo-6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine. Purification on a silica gel column using chloroform/methanol, (8:2), as the eluent gave the title compound as the base: 1H NMR (CDCl3, 400 MHz) δ 8.78 (br s, 1H), 8.47 (br s, 1H), 8.24 (dd, J=9, 2 Hz, 1H), 7.96 (m, 1H), 7.10 (d, J=9 Hz, 1H), 3.12 (m, 4H), 2.50 (t, J=5 Hz, 4H), 2.26 (s, 3H).
  • The base was dissolved in chloroform and treated with 5 M HCl in diethyl ether. The hydrochloride was dried in vacuo and recrystallized from methanol to afford of the title compound. Yield: 9.5%.
    • Example 90 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 55 using 5-trifluoromethyloxindole. Yield: 8%: 1H NMR (D2O, 400 MHz) 7.87 (s, 1H), 7.64 (d, J=9 Hz, 1H), 7.55 (s, 1H), 7.44 (d, J=9 Hz, 1H), 7.29 (d, J=8 Hz, 1H), 7.07 (d, J=8 Hz, 1H), 4.15 (s, 2H), 4.06-3.85 (m, 4H), 3.41-3.26 (m, 4H).
    • Example 91 2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-6-carbonitrile Hydrochloride
  • The title compound was prepared as described for Example 55 using 6-cyanooxindole (1.5 equ) and 1-(6-chloropyridine-3-sulfonyl)-4-methylpiperazine (1 equ; described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203). Purification on a silica gel column using chloroform/methanol/conc. NH3(aq), (76:23:1), as the eluent gave the title compound as the base. The base was dissolved in acetone/chloroform/methanol and treated with 5 M HCl in diethyl ether. The hydrochloride was dried to afford 24 mg (5.1% yield) of title compound: 1H NMR (DMSO-d6, 400 MHz) δ 14.87 (s, 1H), 11.00 (s, 1H), 10.21 (s, 1H), 8.62 (s, 1H), 7.83 (s, 2H), 7.73 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.23 (s, 1H), 3.81-3.67 (m, 2H), 3.57-3.38 (m, 2H), 3.22-3.05 (m, 2H), 2.97-2.85 (m, 2H), 2.77 (s, 3H).
    • Example 92 N-[(1-Ethylpyrrolidin-2-yl)methyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide Hydrochloride
  • To a suspension of ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (100 mg, 0.30 mmol) in toluene (5 mL) was added 2-(aminomethyl)-1-ethylpyrrolidine (78 mg, 0.61 mmol) and the mixture was cooled to 0° C. under a nitrogen atmosphere. Trimethyl aluminium (0.6 mL, 2 M in hexane, 1.2 mmol) was added dropwise during 5 min and the reaction was heated to 70° C. over night. The reaction was quenched with water and an aqueous saturated NaHCO3 solution and is extracted with chloroform. The combined extracts were dried (Na2SO4) and the solvent was evaporated in vacuo. The residue was purified on a silica gel column using chloroform/methanol/conc. NH3(aq), (80:19:1), as the eluent. Fractions containing product were collected and evaporated in vacuo and dried at 25° C. in a vacuum-cabinet over night. The residue was dissolved in methanol/chloroform and treated with 5 M HCl in diethyl ether. The hydrochloride was dried in vacuo to afford 30 mg (20% yield) of title compound as an orange solid: 1H NMR (D2O, 400 MHz) δ 7.65 (s, 1H), 7.42 (d, J=8 Hz, 1H), 7.32 (d, J=8 Hz, 1H), 7.16 (s, 1H), 6.63 (d, J=9 Hz, 1H), 6.53 (d, J=8 Hz, 1H), 3.66-3.52 (m, 4H), 3.49-3.41 (m, 1H), 3.13-3.02 (m, 2H), 2.23-2.16 (m, 1H), 2.05-1.88 (m, 2H), 1.87-1.76 (m, 1H), 1.26 (t, J=7 Hz, 3H).
  • The following Examples, 93-97, was prepared as described for Example 92:
    • Example 93 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)nicotinamide Hydrochloride
  • Starting material: 4-(2-aminoethyl)morpholine. The formed hydrochloride was recrystallized from methanol. Yield: 4.1%: 1H NMR (D2O, 400 MHz) δ 7.70 (s, 1H), 7.52 (d, J=9 Hz, 1H), 7.45 (d, J=8 Hz, 1H), 7.29 (s, 1H), 6.78 (d, J=9 Hz, 1H), 6.64 (d, J=8 Hz, 1H), 4.05-3.75 (m, 4H), 3.65-3.62 (m, 2H), 3.50-3.20 (m, 6H).
    • Example 94 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)nicotinamide Hydrochloride
  • Starting material: 1-methyl-4-(methylamino)piperidine. The formed hydrochloride was recrystallized from methanol. Yield: 3.3%: MS (ES) m/z 410 (M++1).
    • Example 95 5-Nitro-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]pyridin-2-yl}-1H-indol-2-ol Hydrochloride
  • Starting material: 4-(1-pyrrolidinyl)piperidine. The formed hydrochloride was recrystallized from methanol. Yield: 5.2%: MS (EI, 70 eV) m/z (relative intensity) 435 (M+, 1), 298 (6), 282 (7), 207 (5), 174 (14), 154 (17), 124 (17), 110 (100), 98 (75), 84 (26), 70 (61), 52 (23).
    • Example 96 3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1H-indol-2-ol Hydrochloride
  • Starting material: 3-(dimethylamino)pyrrolidine. The formed hydrochloride was recrystallized from methanol. Yield: 1.5%: 1H NMR (DMSO-d6, 400 MHz) δ 11.22 (s, 1H), 8.50 (s, 1H), 8.29 (s, 1H), 8.04 (dd, J=9, 2 Hz, 1H), 7.91 (dd, J=9, 2 Hz, 1H), 7.73 (d, J=9 Hz, 1H), 7.05 (d, J=9 Hz, 1H), 4.05-3.83 (m, 2H), 3.82-3.70 (m, 2H), 3.66-3.54 (m, 1H), 2.80 (br s, 6H), 2.40-2.29 (m, 1H), 2.23-2.10 (m, 1H).
    • Example 97 N-[2-(Dimethylamino)-1-methylethyl]-6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinamide Hydrochloride
  • Starting material: 3-(dimethylamino)pyrrolidine. Yield: 3.2%: 1H NMR (D2O, 400 MHz) δ 7.85 (s, 1H), 7.60 (d, J=9 Hz, 1H), 7.47 (d, J=9 Hz, 1H), 7.36 (s, 1H), 6.84 (d, J=9 Hz, 1H), 6.64 (d, J=9 Hz, 1H), 4.51-4.40 (m, 1H), 3.27-3.12 (m, 2H), 2.88-2.77 (m, 6H), 1.25 (d, J=6 Hz, 3H).
    • Example 98 6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-(2-pyrollindin-1-ylethyl)nicotinamide Fumarate
  • A solution of ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (200 mg, 0.61 mmol) in 2-pyrrolidin-1-yl-ethylamine (1.5 mL) was heated at 120° C. in a closed vessel for 24 h. The mixture was cooled to room temperature and diluted with water and an aqueous solution of NaHCO3 followed by extraction with chloroform. The phases were separated and evaporated in vacuo. Purification on a silica gel column using chloroform/methanol/conc NH3(aq), (100:15:1.5), as the eluent gave 90 mg (37% yield) of the title compound as the base. The base was converted to the fumarate salt according to the procedure described for Example 103: MS (ES) m/z 396 (M++1).
    • Example 99 3-{5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-5-nitro-1H-indol-2-ol Fumarate
  • The title compound was prepared as described for Example 92 using ethyl 6-(2-hydroxy-5-nitro-1H-indol-3-yl)nicotinate (1 eqv), trimethyl aluminium (4 eqv), N-methylpipearzine (2 eqv) and benzene as the solvent. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:12:1.2), as the eluent. Yield: 69% of the title compound as the base. The base was converted to the fumarate salt according to the procedure described for Example 103: MS (ES) m/z 382 (M++1).
    • Example 100 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)nicotinamide Fumarate
  • The title compound was prepared as described for Example 98 using ethyl 6-(2-hydroxy-5-cyano-1H-indol-3-yl)nicotinate and 2-pyrrolidin-1-yl-ethylamine. Yield: 13% of the title compound: 1H NMR (on the base, CDCl3, 300 MHz) δ 10.8 (br s, 1H), 8.80-8.52 (m, 2H), 8.18-7.86 (m, 3H), 7.35-7.18 (m, 1H), 6.98 (d, J=7 Hz, 1H), 6.55 (s, 1H), 3.60-3.35 (m, 2H), 2.83 (m, 6H), 1.80 (br s, 4H).
    • Example 101 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide Hydrochloride
  • To an ice-cooled solution of 5-cyanooxindole (200 mg, 1.26 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (60 mg, 1.5 mmol). The reaction mixture was stirred for 25 min whereafter 6-chloro-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide (303 mg, 1 mmol) was added. The reaction mixture was heated at 130° C. for 1 h and then allowed to cool to room temperature. An aqueous saturated solution of NaHCO3 (50 mL) was added and the water phase was extracted with ethyl acetate. The organic phase was dried (Na2SO4) and purified on a silica gel column using chloroform/methanol/conc NH3(aq), (500:35:3.5 to 500:50:5), as the eluent. The solvents were evaporated in vacuo and the residue was stirred over night in ethyl acetate, filtered and dried to give 160 mg (38% yield) of the title compound as the base. The base, dissolved in chloroform/methanol, was treated with HCl in diethyl ether to give the title compound: MS (ES) m/z 426 (M++1).
    • Example 102 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide Fumarate
  • The title compound was prepared as described for Example 101 using 6-chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide and 5-cyanooxindole. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:10:1), as the eluent followed by another purification on a silica gel column using chloroform/methanol/conc NH3(aq), (100:7:0.7), as the eluent. The base was converted to the fumarate salt according to the procedure described for Example 103: Yield: 20%: MS (ES) m/z 386 (M++1).
    • Example 103 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide Fumarate
  • The title compound was prepared as described for Example 101 using 6-chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide and 5-cyanooxindole. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:10:1), as the eluent: MS (ES) m/z 414 (M++1). The base was dissolved in chloroform (15 mL) and methanol (2 mL) and fumaric acid dissolved in methanol (2 mL) was added. Diethyl ether (20 mL) was added and the formed precipitate was filtered and dried to give the title compound. Yield: 10%: MS (ES) m/z 414 (M++1).
    • Example 104 6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide Fumarate
  • The title compound was prepared as described for Example 101 using 6-chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide and 5-cyanooxindole. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:18:1.8), as the eluent. Yield: 50%: MS (ES) m/z 426 (M++1). The base was converted to the fumarate salt according to the procedure described for Example 103.
    • Example 105 2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile Fumarate
  • The title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane and 5-cyanooxindole. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:15:1.5), as the eluent. Yield: 50%: MS (ES) m/z 412 (M++1). The base was converted to the fumarate salt according to the procedure described for Example 103.
    • Example 106 2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1H-indole-5-carbonitrile
  • The title compound was prepared as described for Example 101 using 4-[(6-chloropyridin-3-yl)sulfonyl]morpholine and 5-cyanooxindole. The reaction mixture was quenched with water and the solvents were evaporated in vacuo. Water was added and the mixture was filtered. The solid material was washed with water, methanol, ethyl acetate and diethyl ether to give the title compound. Yield: 44%: MS (ES) m/z 385 (M++1).
    • Example 107 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1H-indol-2-ol Hydrochloride
  • The title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) and 5-(2-methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (50:3:0.3), as the eluent. The base was dissolved in chloroform/methanol and converted to the hydrochloride salt using HCl in diethyl ether (1 M). Yield: 35% of the title compound: MS (ES) m/z 470 (M++1).
    • Example 108 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-thiazol-4-yl)-1H-indol-2-ol Fumarate
  • The title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) and 5-(1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:7:0.7), as the eluent. The base was converted to the fumarate salt according to the procedure described for Example 103: Yield: 8% of the title compound: MS (ES) m/z 456 (M++1)
    • Example 109 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-oxazol-5-yl)-1H-indol-2-ol
  • The title compound was prepared as described for Example 101 using 1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine (described in: Thunus L., Annales Pharmaceutiques Francaises 1977, 35, 197-203) and 5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one. The crude product was purified on a silica gel column using chloroform/methanol/conc NH3(aq), (100:10:1), as the eluent followed by trituration in ethyl acetate. Yield: 1% of the title compound: MS (ES) m/z 441 (M++1).
    • Example 110 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol Hydrochloride
  • To a suspension of sodium hydride (60% dispersion in oil, 0.048 g, 1.19 mmol, pre-washed with hexane) in N,N-dimethylformamide (2.0 mL) was added 5-nitrooxindole (0.185 g, 1.04 mmol). The formed mixture was stirred for 5 min at room temperature and 2-chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide (0.16 g, 0.7 mmol) was added. The resulting reaction mixture was stirred for 30 minutes at 130° C. (N2 atmosphere). The solvent was removed in vacuo and the residual oil was purified on a silica gel column using chloroform/methanol, (10:1) as the eluent affording the N-oxide product. The N-oxide was dissolved in chloroform (2 mL) and phosphorous trichloride (0.385 g, 2.80 mmol) was added. The reaction mixture was stirred for 30 min at 60° C. followed by extraction with an aqueous saturated NaHCO3 solution. The organic layer was dried (Na2SO4) and concentrated to a yellowish red oil which was purified on a silica gel column using chloroform/methanol, (10:1) as the eluent to give 10 mg (4% yield) of the title compound as the free base as an yellow solid. The base (10 mg, 0.028 mmol) was dissolved in methylene chloride/methanol, (1:1) and treated with 1 M HCl in diethyl ether at 0° C. The resulting yellowish orange crystals were collected by filtration and washed with diethyl ether to obtain 2 mg (16% yield) of the title compound: 1H NMR (DMSO-d6, 400 MHz) δ 11.23 (s, 1H), 10.83 (br s, 1H), 8.36 (s, 2H), 8.10 (dd, J=10, 2 Hz, 1H), 7.94 (dd, J=9, 2 Hz, 1H), 7.87 (d, J=10 Hz, 1H), 7.09 (d, J=9 Hz, 1H), 4.34 (s, 2H), 4.02 (d, J=13 Hz, 2H), 3.77 (t, J=12 Hz, 2H), 3.38 (d, J=11 Hz, 2H), 3.14 (d, J=0 Hz, 2H).
    • Pharmacology Determination of ATP Competition in Scintillation Proximity GSK3β Assay GSK3b Scintillation Proximity Assay.
  • The competition experiments were carried out in duplicate with 10 different concentrations of the inhibitors in clear-bottom microtiter plates (Wallac, Finland). A biotinylated peptide substrate, Biotin-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ser(PO3H2)-Pro-Gln-Leu (AstraZeneca, Lund), was added at a final concentration of 1 μM in an assay buffer containing 1 mU recombinant human GSK3β (Dundee University, UK), 12 mM morpholinepropanesulfonic acid (MOPS), pH 7.0, 0.3 mM EDTA, 0.01% β-mercaptorethanol, 0.004% Brij 35 (a natural detergent), 0.5% glycerol and 0.5 μg BSA/25 μl. The reaction was initiated by the addition of 0.04 μCi [γ-33P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1 μM and assay volume of 25 μl. After incubation for 20 minutes at room temperature, each reaction was terminated by the addition of 25 μl stop solution containing 5 mM EDTA, 50 μM ATP, 0.1% Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham, UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The Km value of ATP for GSK3β, used to calculate the inhibition constants (Ki) of the various compounds, was 20 μM.
  • The following abbreviations have been used:
    MOPS Morpholinepropanesulfonic acid
    EDTA Ethylenediaminetetraacetic acid
    • BSA Bovin Serum Albumin ATP Adenosine Triphosphate SPA Scintillation Proximity Assay
  • GSK3 Glycogen synthase kinase 3
    MP-Carbonate Macroporous triethylamonium methylpolystyrene carbonate
    • PS-Diisopropylethylamine N,N-(Diisopropyl)aminomethylpolystyrene PS-Thiophenol 3-(3-Mercaptophenyl)propanamidomethylpolystyrene
  • PS-Isocyanate Polystyrene methylisocyanate
    • RESULTS
  • Typical Ki values for the compounds of the present invention are in the range of about 0.001 to about 10,000 nM. Other values for Ki are in the range of about 0.001 to about 1000 nM. Further values for Ki are in the range of about 0.010 nM to about 300 nM.

Claims (12)

1-41. (canceled)
42. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia
Figure US20090149460A1-20090611-C00031
wherein the compound is in the form of a base or a pharmaceutically acceptable salt thereof, and wherein:
P is a 6-membered ring containing one nitrogen;
R1 is hydrogen;
R2 is C0-6alkylcyano;
R3 is C0-6alkylNR4R5;
m is 1;
n is 1;
R4 is selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl, C1-6alkylNR14R15, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;
R5 is selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-6alkylheteroaryl, and C1-6alkylNR14R15;
or R4 and R5 together with the N to which they are attached may form a 6-membered heterocyclic group containing one nitrogen and one oxygen; and
wherein any C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, and C0-6alkylheteroaryl group defined under R2 to R5 is optionally substituted by one or more groups Z;
R14 and R15 are independently selected from hydrogen, C1-6alkyl, and C0-6alkylC3-6cycloalkyl, wherein R14 and R15 optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;
Z is independently selected from the group consisting of oxo, halogen, nitro, CN, OR16, C1-6alkyl, C0-6alkylaryl, C0-6alkylC3-6cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR16R17, NR16R17, CONR16R17NR16(CO)R17, O(CO)C1-6alkyl, (CO)OC1-6alkyl, COR16, (SO2)NR16R17, SO2R16, SOR16, (CO)C1-6alkylNR16R17, (SO2)C1-6alkylNR16R17, phenyl, heteroaryl, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, heteroaryl, and heterocyclic groups are optionally substituted by a group Y;
Y is selected from the group consisting of oxo, halogen, nitro, CN, OR16, C1-6alkyl, C0-6alkylaryl, C0-6alkylC3-6cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC1-6alkylNR16R17, NR16R17, CONR16R17, NR16(CO)R17, O(CO)C1-6alkyl, (CO)OC1-6alkyl, COR16, (SO2)NR16R17, SO2R16, SOR16, (CO)C1-6alkylNR16R17 (SO2)C1-6alkylNR16R17, phenyl, C0-6alkylaryl, and heteroaryl, wherein the phenyl, C0-6alkylaryl, and heteroaryl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, CN, OR16, C1-6alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, and trifluoromethoxy;
R16 and R17 are independently selected from hydrogen and C1-6alkyl, and wherein R16 and R17 optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S.
43. A method according to claim 42 wherein in said compound of formula Ia,
R5 is C1-6ylNR14R15, and
R4 is selected from hydrogen, C1-6alkyl; or
R4 and R5 together with the N to which they are attached form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;
and wherein R14 and R15 may together form a 5-membered heterocyclic group containing one or more heteroatoms, selected independently from N, and O
Y is selected from C1-6alkyl, C0-6alkylaryl, NR16R17, phenyl, wherein the phenyl may be optionally substituted with nitro and trifluoromethyl;
wherein R16 and R17 may together form a 5-membered heterocyclic group containing one N heteroatom,
in the form of a base or a pharmaceutically acceptable salt thereof.
44. A method according to claim 42 wherein in said compound of formula Ia,
P is pyridyl; R2 is CN; R3 is C0-6alkylNR4R5; wherein R4 and R5 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O,
in the form of a base or a pharmaceutically acceptable salt thereof.
45. A method according to claim 42 wherein in said compound of formula Ia, R4 and R5 together form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O,
in the form of a base or a pharmaceutically acceptable salt thereof.
46. A method according to claim 42 wherein in said compound of formula Ia is a compound selected from:
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1H-indole-5-carbonitrile;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile;
2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol, or
2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
or a pharmaceutically acceptable salt thereof.
47. A method according to claim 42 wherein in said compound of formula Ia is a compound selected from:
2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-(pyrrolidin-1-ylmethyl)pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol;
6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indol-2-ol;
6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol;
5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol;
3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile;
3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;
3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1H-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1H-indol-2-ol;
5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol;
3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1H-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1H-indol-2-ol;
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)nicotinamide;
6-(2-Hydroxy-5-nitro-1H-indol-3-yl)-N-methyl-N-(1-methylpiperidin-4-yl)nicotinamide;
5-Nitro-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]pyridin-2-yl}-1H-indol-2-ol;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1H-indol-2-ol;
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1H-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1H-indol-2-ol;
6-(5-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile;
5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indol-2-ol, or
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-6-carbonitrile;
or a pharmaceutically acceptable salt thereof.
48. A method of prevention and/or treatment according to claims 42 wherein said condition associated with glycogen synthase kinase-3 is selected from: dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.
49. A method according to claim 48, wherein the condition is Alzheimer's Disease.
50. A method of prevention and/or treatment according to claim 42 wherein said condition is selected from: amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalitic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia or cognitive disorders.
51. A method of prevention and/or treatment according to claim 42 wherein said condition is selected from: predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies or Frontotemporal dementia.
52. A method according to claim 50 wherein the condition is Bipolar Disease.
US12/140,510 2002-03-28 2008-06-17 New Compounds Abandoned US20090149460A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/140,510 US20090149460A1 (en) 2002-03-28 2008-06-17 New Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0200979A SE0200979D0 (en) 2002-03-28 2002-03-28 New compounds
SE0200979-3 2002-03-28
US10/509,268 US7399780B2 (en) 2002-03-28 2003-03-28 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
US12/140,510 US20090149460A1 (en) 2002-03-28 2008-06-17 New Compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/509,268 Continuation US7399780B2 (en) 2002-03-28 2003-03-28 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3

Publications (1)

Publication Number Publication Date
US20090149460A1 true US20090149460A1 (en) 2009-06-11

Family

ID=20287447

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/509,268 Active 2024-05-18 US7399780B2 (en) 2002-03-28 2003-03-28 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
US12/140,510 Abandoned US20090149460A1 (en) 2002-03-28 2008-06-17 New Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/509,268 Active 2024-05-18 US7399780B2 (en) 2002-03-28 2003-03-28 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3

Country Status (32)

Country Link
US (2) US7399780B2 (en)
EP (2) EP1961748A3 (en)
JP (2) JP3989444B2 (en)
KR (1) KR101014525B1 (en)
CN (2) CN100519550C (en)
AR (1) AR038996A1 (en)
AT (1) ATE416171T1 (en)
AU (1) AU2003216026B2 (en)
BR (1) BR0308196A (en)
CA (1) CA2476343C (en)
CY (1) CY1108823T1 (en)
DE (1) DE60325032D1 (en)
DK (1) DK1492785T3 (en)
ES (1) ES2316784T3 (en)
HK (1) HK1071360A1 (en)
IL (2) IL163894A0 (en)
IS (1) IS7471A (en)
MX (1) MXPA04009163A (en)
MY (1) MY144659A (en)
NO (1) NO329884B1 (en)
NZ (1) NZ534664A (en)
PL (1) PL211096B1 (en)
PT (1) PT1492785E (en)
RU (1) RU2338742C2 (en)
SA (1) SA03240054B1 (en)
SE (1) SE0200979D0 (en)
SI (1) SI1492785T1 (en)
TW (1) TWI330081B (en)
UA (1) UA79447C2 (en)
UY (1) UY27740A1 (en)
WO (1) WO2003082853A1 (en)
ZA (1) ZA200407665B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302546D0 (en) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
EP1899806A4 (en) * 2005-06-10 2014-08-13 Pioneer Hi Bred Int Method for use of environmental classification in product selection
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (en) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド GABA receptor-mediated regulation of neurogenesis
WO2007089193A1 (en) * 2006-02-02 2007-08-09 Astrazeneca Ab A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof
US20090221576A1 (en) * 2006-02-02 2009-09-03 Astrazeneca Ab Global Intellectual Property Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts
SA07280004B1 (en) * 2006-02-02 2011-10-29 استرازينيكا ايه بي Citrate Salt of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl)Pyridin-2-Yl]1H-Indole-5-Carbonitrile Citrate
US20120115865A1 (en) * 2006-02-28 2012-05-10 Anna-Lena Berg New Salts of an Indole Derivative and Their Use in Medicine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) * 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080086340A1 (en) * 2006-10-04 2008-04-10 Pioneer Hi-Bred International, Inc. Crop quality insurance
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5406030B2 (en) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008083062A1 (en) 2006-12-29 2008-07-10 Pioneer Hi-Bred International, Inc. Automated location-based information recall
BRPI0810216A2 (en) 2007-04-18 2014-10-21 Astrazeneca Ab PROCESS FOR PREPARING COMPOUND, COMPOUND, AND BIPOLAR DISTURBANCE METHOD
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) * 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2010143803A2 (en) * 2009-06-08 2010-12-16 Industry Foundation Of Chonnam National University New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same
JP2011178752A (en) * 2010-03-03 2011-09-15 Nagoya Univ Nitrogen-containing heterocyclic compound and method for preparing the same
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP2014500277A (en) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Bicyclic compounds as PIM inhibitors
ES2571553T3 (en) 2010-12-21 2016-05-25 Bayer Ip Gmbh Procedure for the preparation of triazinyl substituted oxindoles
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP2014510105A (en) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Azole compounds as PIM inhibitors
DK2970890T3 (en) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc COMPOSITIONS AND PROCEDURES FOR THE PROMOTION AND CULTIVATION OF EPITHEL STEM CELLS
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
RU2648820C2 (en) * 2016-04-14 2018-03-28 Общество с ограниченной ответственностью "Научно-исследовательский центр "Парк активных молекул" Means of anti-clonogenic activity in respect of tumor human cells
MX2019007890A (en) 2016-12-30 2020-01-20 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells.
CN108440401A (en) * 2018-04-13 2018-08-24 华东理工大学 The preparation method of 5- [(4- ethyl piperazidine -1- bases) methyl] pyridine -2- amine
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288599A (en) * 1979-03-09 1981-09-08 Ishihara Sangyo Kaisha Ltd. Process for producing pyridine derivatives having a trifluoromethyl group at β-position thereof
US6265411B1 (en) * 1996-05-06 2001-07-24 Zeneca Limited Oxindole derivatives
US6294532B1 (en) * 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US20050070559A1 (en) * 2001-12-21 2005-03-31 Stefan Berg Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
US20050075351A1 (en) * 2001-12-20 2005-04-07 Stefan Berg Use
US6987110B2 (en) * 2002-06-05 2006-01-17 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
US7205314B2 (en) * 2001-12-20 2007-04-17 Astrazeneca Ab Compounds for the treatment of dementia related diseases
US7342022B2 (en) * 2001-12-21 2008-03-11 Astrazeneca Ab Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3
US20080275041A1 (en) * 2003-09-24 2008-11-06 Astrazeneca Ab 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5565580A (en) * 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
BR9506936A (en) 1994-02-23 1997-09-09 Pfizer Quinazoline derivatives replaced with 4-heterocyclyl processes for their preparation and use as anti-cancer agents
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP1105376B1 (en) 1998-08-20 2005-02-09 Sumitomo Pharmaceuticals Company, Limited Oxindole derivatives as growth hormone releasers
DE60042620D1 (en) 1999-05-21 2009-09-03 Bristol Myers Squibb Co Pyrrolotriazine as a kinase inhibitor.
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1136493A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
JP3984157B2 (en) * 2000-07-27 2007-10-03 エフ．ホフマン−ラ ロシュ アーゲー 3-Indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3 beta
WO2002030868A1 (en) 2000-10-13 2002-04-18 Bristol-Myers Squibb Company Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288599A (en) * 1979-03-09 1981-09-08 Ishihara Sangyo Kaisha Ltd. Process for producing pyridine derivatives having a trifluoromethyl group at β-position thereof
US6265411B1 (en) * 1996-05-06 2001-07-24 Zeneca Limited Oxindole derivatives
US6294532B1 (en) * 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US20050075351A1 (en) * 2001-12-20 2005-04-07 Stefan Berg Use
US7205314B2 (en) * 2001-12-20 2007-04-17 Astrazeneca Ab Compounds for the treatment of dementia related diseases
US20050070559A1 (en) * 2001-12-21 2005-03-31 Stefan Berg Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
US7342022B2 (en) * 2001-12-21 2008-03-11 Astrazeneca Ab Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3
US6987110B2 (en) * 2002-06-05 2006-01-17 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
US20080275041A1 (en) * 2003-09-24 2008-11-06 Astrazeneca Ab 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352

Also Published As

Publication number Publication date
ES2316784T3 (en) 2009-04-16
ATE416171T1 (en) 2008-12-15
SE0200979D0 (en) 2002-03-28
IL163894A (en) 2010-11-30
AU2003216026A1 (en) 2003-10-13
DK1492785T3 (en) 2009-03-02
JP2007224051A (en) 2007-09-06
AU2003216026B2 (en) 2008-12-11
AR038996A1 (en) 2005-02-02
PL372966A1 (en) 2005-08-08
CA2476343A1 (en) 2003-10-09
EP1492785B9 (en) 2009-10-21
EP1492785A1 (en) 2005-01-05
JP2005526814A (en) 2005-09-08
MXPA04009163A (en) 2004-12-07
JP3989444B2 (en) 2007-10-10
MY144659A (en) 2011-10-31
NO20044432L (en) 2004-10-19
IS7471A (en) 2004-10-15
PL211096B1 (en) 2012-04-30
UA79447C2 (en) 2007-06-25
HK1071360A1 (en) 2005-07-15
IL163894A0 (en) 2005-12-18
RU2338742C2 (en) 2008-11-20
TW200306180A (en) 2003-11-16
SI1492785T1 (en) 2009-06-30
CA2476343C (en) 2011-05-03
US20050153987A1 (en) 2005-07-14
WO2003082853A8 (en) 2004-05-06
EP1961748A3 (en) 2009-10-07
CN1923812A (en) 2007-03-07
PT1492785E (en) 2009-02-02
TWI330081B (en) 2010-09-11
US7399780B2 (en) 2008-07-15
EP1961748A2 (en) 2008-08-27
NO329884B1 (en) 2011-01-17
SA03240054B1 (en) 2009-04-04
KR101014525B1 (en) 2011-02-14
ZA200407665B (en) 2005-08-29
CY1108823T1 (en) 2014-04-09
RU2004125146A (en) 2005-06-27
KR20040094884A (en) 2004-11-10
NZ534664A (en) 2007-06-29
EP1492785B1 (en) 2008-12-03
CN1642938A (en) 2005-07-20
WO2003082853A1 (en) 2003-10-09
CN100519550C (en) 2009-07-29
UY27740A1 (en) 2003-10-31
DE60325032D1 (en) 2009-01-15
BR0308196A (en) 2005-01-11

Similar Documents

Publication Publication Date Title
US7399780B2 (en) 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
US7595319B2 (en) Compounds having selective inhibiting effect at GSK3
EP3813819A1 (en) Inhibitors of cyclin-dependent kinases
US7683067B2 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
US7345050B2 (en) Pyrimidine compounds
JPWO2004069824A1 (en) Pyrazole derivative
US20100087396A1 (en) Novel Compounds Having Selective Inhibiting Effect at GSK3
US20220348560A1 (en) N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
RU2806754C1 (en) N-(1h-imidazol-2-yl)benzamide and pharmaceutical composition containing it as active ingredient

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION